≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Hypertension, Pulmonary Arterial

DOID EFO Endpoint Browser PheWeb

I9_HYPTENSPUL

hypertension: Persistently high systemic arterial blood pressure. Based on multiple readings (blood pressure determination), hypertension is currently defined as when systolic pressure is consistently greater than 140 mm Hg or when diastolic pressure is consistently 90 mm Hg or more.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — I27.0
  • Hospital discharge: ICD-9 — 4160A
  • Hospital discharge: ICD-8 — 42600
  • Cause of death: ICD-10 — I27.0
  • Cause of death: ICD-9 — 4160A
  • Cause of death: ICD-8 — 42600

2 out of 7 registries used, show all original rules.

333

4. Check minimum number of events

None

333

5. Include endpoints

None

333

6. Filter based on genotype QC (FinnGen only)

319

Control definitions (FinnGen only)

Control exclude
I9_HYPERTENSION

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
I27
Name in latin
Hypertensio pulmonalis primaria

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2950 1579 1316
Only index persons 1759 1100 659
Unadjusted period prevalence (%)
Whole population 0.04 0.05 0.04
Only index persons 0.03 0.04 0.03
Median age at first event (years)
Whole population 65.26 67.03 63.32
Only index persons 68.00 69.52 65.46

-FinnGen-

Key figures

All Female Male
Number of individuals 319 207 112
Unadjusted period prevalence (%) 0.07 0.07 0.05
Median age at first event (years) 61.78 60.58 63.99

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
333
Matched controls
3330
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
303.4
307.7
159
10
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
307.7
311
*
G04BE03
ATC
sildenafil; oral
186.2
272.6
134
12
205
Kela drug reimbursment
Chronic hypertension
+∞
225.5
190
*
C03DA01
ATC
spironolactone; oral
21.1
173.9
170
157
B01AA03
ATC
warfarin; systemic
14.6
141.9
200
310
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
14.2
138.2
193
294
C03CA01
ATC
furosemide; systemic
16.0
131.3
260
606
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
491.6
107.9
102
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
15.0
107.2
112
109
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
217.9
106.3
105
7
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
10.6
106.0
174
311
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
52.7
97.6
57
13
C02KX04
ATC
macitentan; oral
+∞
89.7
82
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
8.6
87.6
178
392
I50.9
ICD-10 Finland
Heart failure, unspecified
9.2
84.3
137
235
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
8.7
80.3
137
247
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
15.1
79.2
77
65
R06.0
ICD-10 Finland
Dyspnoea
6.9
70.4
194
557
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
11.6
70.3
82
91
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
12.0
68.8
78
83
C01AA05
ATC
digoxin; systemic
9.0
65.9
97
145
I27.8
ICD-10 Finland
Other specified pulmonary heart diseases
262.9
64.6
64
*
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
12.5
63.0
68
67
J96.1
ICD-10 Finland
Chronic respiratory failure
19.2
62.1
51
31
GD1AA
NOMESCO Finland
Thorax X-ray examination
7.7
61.8
261
1069
I50.0
ICD-10 Finland
Congestive heart failure
9.5
59.6
81
109
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
20.4
57.8
46
26
WX872
NOMESCO Finland
Intensive care
13.5
53.8
54
47
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
14.2
52.5
51
42
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
11.9
51.9
57
57
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
14.2
51.6
50
41
A12BA01
ATC
potassium chloride; oral
23.0
49.4
37
18
C02KX01
ATC
bosentan; oral
+∞
44.8
42
*
G04BE08
ATC
tadalafil; oral
252.5
44.1
44
*
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
7.5
43.6
71
116
M04AA01
ATC
allopurinol; systemic
6.6
43.6
82
156
I48
ICD-10 Finland
Atrial fibrillation and flutter
4.8
41.1
131
395
C08CA02
ATC
felodipine; oral
11.6
40.4
44
43
WX740
NOMESCO Finland
Nitrogen oxide therapy
151.0
38.6
40
*
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
13.8
38.2
37
30
GD1AD
NOMESCO Finland
Thorax CT examination
8.0
37.7
56
82
AN1
HP
Coronary angiography
6.6
37.1
68
125
I10
ICD-10 Finland
Essential (primary) hypertension
4.0
35.0
180
754
TPH04
NOMESCO Finland
Cathetrisation of vein
4.4
34.2
119
377
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.9
33.6
50
73
AP2
HP
Catheterization of the right side of the heart
100.6
33.5
36
*
XF622
NOMESCO Finland
Measurement of minute volume of heart
129.9
33.4
35
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.3
32.8
79
186
C08CA05
ATC
nifedipine; systemic
9.4
32.4
41
49
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
7.3
32.2
51
80
C07AB07
ATC
bisoprolol; oral
3.8
31.2
205
989
R4110
NOMESCO Finland
Physiotherapy
3.8
30.5
146
572
XF614
NOMESCO Finland
Measurement of pulmonary artery pressure
330.9
30.3
30
*
Z3226
NOMESCO Finland
Physiotherapist
4.2
30.3
106
334
ZXE40
NOMESCO Finland
More than seven and less than nine hours
13.1
30.3
30
25
XF404
NOMESCO Finland
Ambulatory ECG
5.9
30.0
60
119
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.7
29.7
144
567
383
Kela drug reimbursment
Selexipag
+∞
29.6
28
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.9
28.2
41
58
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.4
27.8
86
246
C08CA01
ATC
amlodipine; oral
3.7
27.7
126
472
TPH07
NOMESCO Finland
Cathetrisation of artery
5.1
27.7
66
153
B01AC27
ATC
selexipag; oral
+∞
27.5
26
*
C02KX02
ATC
ambrisentan; oral
+∞
27.5
26
*
Z2446
NOMESCO Finland
Social worker
6.3
27.2
50
91
H02AB06
ATC
prednisolone; systemic
3.5
27.2
204
1042
C08DB01
ATC
diltiazem; oral
8.5
26.4
36
47
B01AC11
ATC
iloprost; inhalant, parenteral
+∞
26.4
25
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
25.5
78
220
C09AA02
ATC
enalapril; systemic
4.6
25.2
70
183
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.5
24.7
43
74
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.7
24.5
103
363
XF400
NOMESCO Finland
ECG with 12 standard connections
3.9
24.1
89
287
B01AB05
ATC
enoxaparin; parenteral
3.3
24.1
143
624
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.3
24.0
134
563
I34.09
ICD-10 Finland
Mitral (valve) insufficiency
7.5
23.8
36
53
103
Kela drug reimbursment
Diabetes, insulin-treated
3.6
23.7
100
352
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.8
23.4
39
64
Z94.2
ICD-10 Finland
Lung transplant status
+∞
23.2
22
*
L04AA06
ATC
mycophenolic acid; systemic
28.3
23.1
31
12
R04.0
ICD-10 Finland
Epistaxis
5.2
23.1
52
114
I11.0
ICD-10 Finland
Hypertensive heart disease with (congestive) heart failure
246.2
22.9
23
*
A46
ICD-10 Finland
Erysipelas
4.0
22.9
78
237
ZXE20
NOMESCO Finland
More than three and less than five hours
4.0
22.8
76
227
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.7
22.8
90
303
TGC00
NOMESCO Finland
Bronchial lavation
9.7
22.4
27
30
XG466
NOMESCO Finland
Sleep oxymetry
9.7
22.4
27
30
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
8.7
22.1
29
36
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.7
22.0
56
136
ZX120
NOMESCO Finland
Intravenous
4.3
21.5
63
171
K93
ICPC
Pulmonary embolism
53.8
21.4
25
5
TFP20
NOMESCO Finland
Cardiodefibrillation
5.7
21.3
43
85
334
Kela drug reimbursment
Treprostinil
+∞
21.1
20
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
5.2
21.0
47
102
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.7
20.5
53
130
B01AC21
ATC
treprostinil; parenteral
+∞
20.0
19
*
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
20.0
19
*
FN1BC
NOMESCO Finland
Extensive angiography of hear and/or coronary arteries
7.2
19.9
31
47
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.4
19.9
92
340
K78
ICPC
Atrial fibrillation/flutter
4.8
19.8
49
116
Z3231
NOMESCO Finland
Registered nurse
3.0
19.6
119
515
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
5.7
19.6
39
76
WX892
NOMESCO Finland
Monitored bed care
5.4
19.5
41
84
Z2221
NOMESCO Finland
Medical doctor
3.0
19.5
122
537
XF620
NOMESCO Finland
Examination of circulation with color method
49.2
19.5
23
5
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.9
19.2
64
190
207
Kela drug reimbursment
Chronic arrhythmias
3.4
19.0
81
284
XG410
NOMESCO Finland
Flow-volume spirometry
6.6
18.9
32
53
C02KX05
ATC
riociguat; oral
+∞
18.9
18
*
GD2SN
NOMESCO Finland
Lung ventilation SPECT
41.0
18.8
23
6
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
200.8
18.7
19
*
127
Kela drug reimbursment
Transplant complication
46.9
18.5
22
5
A10AB05
ATC
insulin aspart; parenteral
6.0
18.3
34
62
C07AB02
ATC
metoprolol; systemic
3.3
17.5
79
286
A10BB01
ATC
glibenclamide; oral
8.0
17.2
24
32
M10.9
ICD-10 Finland
Gout, unspecified
5.7
16.9
33
63
S97
ICPC
Chronic ulcer skin
5.4
16.8
35
71
I27.1
ICD-10 Finland
Kyphoscoliotic heart disease
+∞
16.8
16
*
SPAT1262
SPAT
Handing over of treatment supplies
3.4
16.1
68
235
R28
ICPC
Limited function/disability (R)
18.4
15.9
24
14
42600
ICD-8 Finland
Pulmonary heart disease, Cor pulmonale
+∞
15.7
15
*
62
HP
Catheterization and pressure measurement of the right side of the heart
89.4
15.7
17
*
B01AB10
ATC
tinzaparin; parenteral
3.6
15.7
58
184
A10BB12
ATC
glimepiride; oral
5.6
15.6
31
60
C03AA03
ATC
hydrochlorothiazide; oral
5.6
15.6
31
60
J01MA12
ATC
levofloxacin; systemic
3.0
15.4
84
338
I50.1
ICD-10 Finland
Left ventricular failure
5.2
15.3
33
69
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
15.0
98
433
K99
ICPC
Cardiovascular disease other
17.5
15.0
23
14
C02AC05
ATC
moxonidine; oral
59.5
14.9
17
*
AP3
HP
Catheterization of the right and left side of the heart
59.5
14.9
17
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
6.5
14.9
25
41
L04AX01
ATC
azathioprine; systemic
6.0
14.9
27
48
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
14.7
14
*
GD1UN
NOMESCO Finland
Lung circulation SPECT
37.9
14.6
18
5
FB1BC
NOMESCO Finland
Extensive angiography of arteria pulmonalis
156.6
14.6
15
*
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.8
14.3
27
50
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.0
14.0
75
297
ZXD05
NOMESCO Finland
Urgent procedure
2.5
13.7
118
594
FB1AD
NOMESCO Finland
CT examination of arteria pulmonalis
10.7
13.7
26
26
A10BH05
ATC
linagliptin; oral
6.2
13.7
24
41
L04AD02
ATC
tacrolimus; systemic
78.4
13.7
15
*
FBB20
NOMESCO Finland
Thrombendarterectomy of pulmonary artery in chronic obstruction
+∞
13.6
13
*
K82
ICPC
Pulmonary heart disease
+∞
13.6
13
*
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
22.3
13.5
19
9
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
5.5
13.4
27
53
R5140
NOMESCO Finland
Monitoring the use of the aid
3.5
13.4
50
159
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.2
13.4
60
214
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
17.6
13.1
20
12
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
17.6
13.1
20
12
C09BA02
ATC
enalapril and diuretics; systemic
6.5
13.1
22
36
ZX108
NOMESCO Finland
Inhalation
20.1
13.1
19
10
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.7
13.0
45
136
I20.99
ICD-10 Finland
Angina pectoris, unspecified
4.6
13.0
32
75
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.1
13.0
38
102
R50.9
ICD-10 Finland
Fever, unspecified
2.9
12.8
72
292
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.5
12.8
47
148
B01AB04
ATC
dalteparin; parenteral
4.7
12.7
30
68
3AC01, ,
NOMESCO Finland
25.5
12.6
17
7
M34.0
ICD-10 Finland
Progressive systemic sclerosis
+∞
12.6
12
*
GD1FN
NOMESCO Finland
Lung ventilation isotope imaging
134.9
12.5
13
*
A10AE05
ATC
insulin detemir; parenteral
5.7
12.5
24
45
R03AC02
ATC
salbutamol; inhalant
2.3
12.4
204
1348
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.8
12.4
41
120
R4190
NOMESCO Finland
Nutritional therapy
4.9
12.4
28
61
ZXD10
NOMESCO Finland
Scheduled procedure
2.3
12.3
145
833
C01BD01
ATC
amiodarone; systemic
11.7
12.2
22
20
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
18.9
12.2
18
10
A10BA02
ATC
metformin; oral
2.6
12.1
87
400
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
4.5
12.0
30
71
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
6.2
11.9
21
36
P01BA02
ATC
hydroxychloroquine; oral
3.5
11.9
44
139
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.5
11.8
43
134
R02
ICPC
Shortness of breath/dyspnoea
2.9
11.8
65
260
A10AC01
ATC
insulin (human); parenteral
4.1
11.8
34
90
PH7FT
NOMESCO Finland
Inmplantation of filter to inferior vena cava with radiological guidance
+∞
11.5
11
*
FXA20
NOMESCO Finland
Total cardiopulmonary bypass in deep hypothermia and circulatory arrest at concurrent surgical procedure
+∞
11.5
11
*
I34.00
ICD-10 Finland
Mitral (valve) incompetence NOS or of specified cause, except rheumatic
12.4
11.5
20
17
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.1
11.4
53
192
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
17.8
11.3
17
10
Z73.3
ICD-10 Finland
Stress, not elsewhere classified
13.4
11.3
19
15
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
3.5
11.1
40
124
T90
ICPC
Diabetes non-insulin dependent
2.6
11.1
73
320
N02AX02
ATC
tramadol; systemic, rectal
2.2
11.0
151
914
C08CA13
ATC
lercanidipine; oral
3.4
10.7
40
127
J45.9
ICD-10 Finland
Asthma, unspecified
2.5
10.6
79
367
R03BB04
ATC
tiotropium bromide; inhalant
3.0
10.6
50
183
G47.3
ICD-10 Finland
Sleep apnoea
2.6
10.6
73
327
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
113.4
10.5
11
*
4019X
ICD-9 Finland
Essential hypertension, Unspecified
+∞
10.5
10
*
FB1AC
NOMESCO Finland
Angiography of arteria pulmonalis
+∞
10.5
10
*
4160A
ICD-9 Finland
Chronic pulmonary heart disease, Primary pulmonary hypertension
+∞
10.5
10
*
WZC05
NOMESCO Finland
Specialty-specific consultation based on referral by dentist or doctor
4.3
10.4
28
70
C01DA14
ATC
isosorbide mononitrate; oral
2.8
10.4
61
251
M34.1
ICD-10 Finland
CR(E)ST syndrome
33.7
10.4
13
*
C02EA02, ,
ATC
33.7
10.4
13
*
E66.8
ICD-10 Finland
Other obesity
5.5
10.2
20
38
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.6
10.1
66
287
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
8.0
10.1
22
29
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
41.4
10.0
12
*
C07AA07
ATC
sotalol; systemic
4.8
9.9
23
51
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
9.9
127
741
N02AA05
ATC
oxycodone; systemic
2.4
9.9
81
392
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.6
9.7
33
98
WX882
NOMESCO Finland
High dependency care
7.5
9.7
22
31
D68.8
ICD-10 Finland
Other specified coagulation defects
18.2
9.5
14
8
WX721
NOMESCO Finland
Oxygen concentrator therapy
31.0
9.5
12
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
5.1
9.4
20
41
C03EB01
ATC
furosemide and potassium-sparing agents; systemic
4.3
9.4
25
62
PH3BC
NOMESCO Finland
Extensive flebography of internal organs with X-ray
+∞
9.4
9
*
C01DA02
ATC
glyceryl trinitrate; oral, oral aerosol, sublingual, transdermal
2.4
9.3
78
380
J01MA14
ATC
moxifloxacin; systemic
3.0
9.3
44
161
C09AA05
ATC
ramipril; oral
2.4
9.3
78
381
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.0
9.3
27
72
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
2.9
9.2
48
185
R99
ICPC
Respiratory disease other
11.9
9.2
16
14
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
3.3
9.1
36
118
N18.8
ICD-10 Finland
Other chronic renal failure
16.2
9.1
14
9
L04AD01
ATC
ciclosporin; systemic
16.2
9.1
14
9
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.9
9.1
45
169
A10AE04
ATC
insulin glargine; parenteral
3.7
9.0
29
83
C07AG02
ATC
carvedilol; oral
8.3
9.0
19
24
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.1
9.0
109
619
TLC00
NOMESCO Finland
Insertion of intrauterine device
4.2
9.0
24
60
379
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
5.1
8.9
19
39
I50
ICD-10 Finland
Heart failure
4.9
8.9
20
43
J01FF01
ATC
clindamycin; systemic
2.2
8.9
92
490
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
8.0
8.8
19
25
ZXE00
NOMESCO Finland
One hour or less
2.0
8.7
138
862
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.6
8.7
58
254
WX725
NOMESCO Finland
Noninvasive ventilation
4.0
8.7
25
66
XF402
NOMESCO Finland
ECG with work load test
2.9
8.6
42
156
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.0
8.5
25
67
TFC20
NOMESCO Finland
Catheterisation of both sides of heart
92.3
8.5
9
*
A10BH01
ATC
sitagliptin; oral
3.5
8.4
30
92
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.5
8.4
60
271
C09CA01
ATC
losartan; oral
2.3
8.4
71
347
FL1AC
NOMESCO Finland
Left cardioangiography
9.8
8.4
16
17
XQ841
NOMESCO Finland
Examination of dermatosis with microscope
+∞
8.4
8
*
H11.3
ICD-10 Finland
Conjunctival haemorrhage
3.9
8.3
25
68
AA1AD
NOMESCO Finland
CT of head and brain
2.1
8.3
103
588
D64.9
ICD-10 Finland
Anaemia, unspecified
2.8
8.2
45
178
K29
ICPC
Cardiovascular sympt/complt other
4.7
8.2
19
42
RK110, ,
NOMESCO Finland
17.7
8.1
12
7
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
4.0
8.1
23
60
C09DA06
ATC
candesartan and diuretics; oral
4.5
8.1
20
47
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
6.4
8.0
20
33
I83.0
ICD-10 Finland
Varicose veins of lower extremities with ulcer
8.1
8.0
17
22
A07AA09
ATC
vancomycin; oral
13.5
7.9
13
10
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
7.9
142
921
WX000
NOMESCO Finland
Monitoring vital functions without anesthesy
4.4
7.8
20
48
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.4
7.8
20
48
M10.0
ICD-10 Finland
Idiopathic gout
6.6
7.8
19
30
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
6.2
7.8
20
34
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.8
7.8
42
165
XW5WT
NOMESCO Finland
Other blood specimen with radiologicl guidance
46.1
7.7
9
*
C09DA01
ATC
losartan and diuretics; oral
3.7
7.7
25
72
WW200
NOMESCO Finland
Immunization
7.0
7.7
18
27
XX1XW
NOMESCO Finland
Extensive written report from radiologist
8.3
7.7
16
20
I26
ICD-10 Finland
Pulmonary embolism
12.2
7.6
13
11
C07AB03
ATC
atenolol; systemic
4.4
7.6
19
45
SPAT1255
SPAT
Intravenous administration of medicine
3.5
7.6
27
83
XF640, ,
NOMESCO Finland
6.7
7.5
18
28
XX4BW, ,
NOMESCO Finland
81.8
7.4
8
*
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
81.8
7.4
8
*
I28.9
ICD-10 Finland
Disease of pulmonary vessels, unspecified
81.8
7.4
8
*
RK320, ,
NOMESCO Finland
13.8
7.4
12
9
C10AA01
ATC
simvastatin; oral
1.9
7.4
127
807
Z3229
NOMESCO Finland
Other healthcare associate professional
2.9
7.4
36
134
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.7
7.3
41
164
GD1CN
NOMESCO Finland
Lung circulation isotope imaging
+∞
7.3
7
*
I87.0
ICD-10 Finland
Postthrombotic syndrome
+∞
7.3
7
*
A41.9
ICD-10 Finland
Sepsis, unspecified
4.5
7.3
18
42
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.5
7.3
18
42
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
7.3
44
183
R07.4
ICD-10 Finland
Chest pain, unspecified
2.0
7.3
96
556
C08CA10
ATC
nilvadipine; oral
20.5
7.2
10
5
C09CA03
ATC
valsartan; oral
3.7
7.1
23
66
I42.0
ICD-10 Finland
Dilated cardiomyopathy
7.2
7.1
16
23
I36.1
ICD-10 Finland
Nonrheumatic tricuspid (valve) insufficiency
7.2
7.1
16
23
XFE00
NOMESCO Finland
Epicardial ultrasonography
7.2
7.1
16
23
B01AF02
ATC
apixaban; oral
2.4
7.1
51
231
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.5
7.1
47
205
N19
ICD-10 Finland
Unspecified kidney failure
6.3
6.9
17
28
TK800
NOMESCO Finland
Hemodialysis
11.3
6.8
12
11
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
3.7
6.8
22
63
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.8
84
474
Q25.0
ICD-10 Finland
Patent ductus arteriosus
40.9
6.8
8
*
L04AA01
ATC
[U] ciclosporin
17.1
6.8
10
6
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.2
6.8
66
340
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
23.1
6.7
9
*
61
HP
Catheterization and pressure measurement of the left side of the heart
8.1
6.7
14
18
I20.09
ICD-10 Finland
Unstable angina
4.0
6.6
19
50
TFC10
NOMESCO Finland
Catheterisation of left atrium or ventricle
9.0
6.6
13
15
ZY010
NOMESCO Finland
Hospital outpatient
3.8
6.6
20
55
FXD00
NOMESCO Finland
Use of ECHLA without concurrent surgical procedure
71.2
6.4
7
*
A07AA02
ATC
nystatin; oral
3.1
6.4
27
92
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.4
6.4
48
221
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.7
6.4
20
56
M10
ICD-10 Finland
Gout
5.7
6.4
17
31
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
5.7
6.4
17
31
WX002
NOMESCO Finland
Sedation and analgesia
2.1
6.3
66
349
N05CF01
ATC
zopiclone; oral
1.8
6.3
117
755
Q21.10
ICD-10 Finland
Persistent ostium secundum
18.4
6.3
9
5
I83.2
ICD-10 Finland
Varicose veins of lower extremities with both ulcer and inflammation
18.4
6.3
9
5
I28.8
ICD-10 Finland
Other specified diseases of pulmonary vessels
+∞
6.3
6
*
FXE00
NOMESCO Finland
Use of ECLA
+∞
6.3
6
*
3A064, ,
NOMESCO Finland
27.2
6.3
8
*
7AX01, ,
NOMESCO Finland
27.2
6.3
8
*
I35.0
ICD-10 Finland
Aortic (valve) stenosis
3.4
6.3
22
67
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.2
6.2
25
83
R58
ICD-10 Finland
Haemorrhage, not elsewhere classified
7.9
6.2
13
17
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.0
6.1
78
443
UJF32
NOMESCO Finland
Coloscopy
1.9
6.1
89
530
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
10.3
6.1
11
11
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.5
6.1
38
161
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
3.8
6.0
18
49
C09CA07
ATC
telmisartan; oral
3.8
6.0
18
49

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
spironolactone; oral
C03DA01 [21601534]
3.0e+00
3.3e+00
3.5e+00
—
3.7e+00
4.1e+00
3.6e+00
cases:10.16%
controls:0.54%
cases:13.92%
controls:0.57%
cases:5.70%
controls:0.19%
—
—
cases:9.12%
controls:0.25%
cases:28.13%
controls:0.68%
cases:32.05%
controls:1.31%
32
17
283
3133
44
18
272
3142
18
6
298
3154
—
28
8
279
3146
81
21
207
3083
75
36
159
2718
Cardiology
6 [38004451]
1.8e+00
3.1e+00
3.3e+00
—
4.2e+00
3.5e+00
2.9e+00
cases:33.65%
controls:8.03%
cases:44.94%
controls:3.64%
cases:15.82%
controls:0.70%
—
—
cases:22.80%
controls:0.44%
cases:57.29%
controls:3.99%
cases:63.68%
controls:8.97%
106
253
209
2897
142
115
174
3045
50
22
266
3138
—
70
14
237
3140
165
124
123
2980
149
247
85
2507
furosemide; oral, parenteral
C03CA01 [21601518]
2.3e+00
3.1e+00
3.1e+00
1.0e+50
3.2e+00
3.5e+00
3.0e+00
cases:30.79%
controls:4.32%
cases:40.82%
controls:2.91%
cases:16.14%
controls:0.85%
cases:1.58%
controls:0.00%
cases:23.13%
controls:1.20%
cases:56.94%
controls:3.80%
cases:56.84%
controls:6.43%
97
136
218
3014
129
92
187
3068
51
27
265
3133
5
0
311
3160
71
38
236
3116
164
118
124
2986
133
177
101
2577
Pulmonary Disease
29 [38004472]
1.7e+00
2.8e+00
3.1e+00
1.0e+50
3.7e+00
3.6e+00
2.9e+00
cases:26.67%
controls:6.10%
cases:35.76%
controls:3.20%
cases:13.92%
controls:0.73%
cases:22.47%
controls:0.00%
cases:22.80%
controls:0.73%
cases:56.60%
controls:3.54%
cases:59.40%
controls:7.37%
84
192
231
2958
113
101
203
3059
44
23
272
3137
71
0
245
3160
70
23
237
3131
163
110
125
2994
139
203
95
2551
sildenafil; oral
G04BE03 [21602648]
1.8e+00
2.3e+00
3.0e+00
—
4.3e+00
3.5e+00
2.8e+00
cases:9.52%
controls:1.78%
cases:12.66%
controls:1.46%
cases:4.43%
controls:0.22%
—
—
cases:18.89%
controls:0.32%
cases:33.68%
controls:1.45%
cases:36.32%
controls:3.20%
30
56
285
3094
40
46
276
3114
14
7
302
3153
—
58
10
249
3144
97
45
191
3059
85
88
149
2666
Thorax X-ray examination
GD1AA [2001303617]
1.6e+00
2.6e+00
3.5e+00
—
3.5e+00
3.1e+00
2.5e+00
cases:27.62%
controls:7.11%
cases:27.85%
controls:2.85%
cases:9.18%
controls:0.32%
—
—
cases:8.79%
controls:0.29%
cases:35.42%
controls:2.51%
cases:48.29%
controls:7.19%
87
224
228
2926
88
90
228
3070
29
10
287
3150
—
27
9
280
3145
102
78
186
3026
113
198
121
2556
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.7e+00
2.7e+00
3.7e+00
—
3.2e+00
2.9e+00
2.3e+00
cases:15.87%
controls:3.27%
cases:20.25%
controls:1.65%
cases:13.92%
controls:0.38%
—
—
cases:10.10%
controls:0.44%
cases:28.13%
controls:2.19%
cases:43.59%
controls:7.15%
50
103
265
3047
64
52
252
3108
44
12
272
3148
—
31
14
276
3140
81
68
207
3036
102
197
132
2557
warfarin; oral, parenteral
B01AA03 [21600965]
2.1e+00
2.6e+00
2.4e+00
—
3.1e+00
3.2e+00
2.9e+00
cases:28.25%
controls:4.76%
cases:33.54%
controls:3.48%
cases:9.49%
controls:0.98%
—
—
cases:18.24%
controls:1.01%
cases:48.96%
controls:3.70%
cases:51.28%
controls:5.27%
89
150
226
3000
106
110
210
3050
30
31
286
3129
—
56
32
251
3122
141
115
147
2989
120
145
114
2609
Essential (primary) hypertension
I10 [45591453]
2.2e+00
2.7e+00
3.1e+00
—
3.8e+00
2.5e+00
1.6e+00
cases:29.21%
controls:4.48%
cases:21.52%
controls:1.80%
cases:6.33%
controls:0.32%
—
—
cases:9.12%
controls:0.22%
cases:22.57%
controls:2.38%
cases:29.91%
controls:7.77%
92
141
223
3009
68
57
248
3103
20
10
296
3150
—
28
7
279
3147
65
74
223
3030
70
214
164
2540
digoxin; oral, parenteral
C01AA05 [21600234]
2.2e+00
2.3e+00
2.0e+00
—
3.1e+00
2.8e+00
2.7e+00
cases:8.89%
controls:1.08%
cases:7.91%
controls:0.82%
cases:1.90%
controls:0.25%
—
—
cases:5.21%
controls:0.25%
cases:11.46%
controls:0.81%
cases:13.68%
controls:1.02%
28
34
287
3116
25
26
291
3134
6
8
310
3152
—
16
8
291
3146
33
25
255
3079
32
28
202
2726
Physiotherapist
Z3226 [2001311560]
1.2e+00
2.2e+00
2.3e+00
1.0e+50
3.7e+00
3.0e+00
2.5e+00
cases:7.94%
controls:2.44%
cases:5.70%
controls:0.66%
cases:2.22%
controls:0.22%
cases:4.75%
controls:0.00%
cases:5.86%
controls:0.16%
cases:14.58%
controls:0.81%
cases:16.24%
controls:1.60%
25
77
290
3073
18
21
298
3139
7
7
309
3153
15
0
301
3160
18
5
289
3149
42
25
246
3079
38
44
196
2710
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
1.2e+00
2.0e+00
3.6e+00
1.0e+50
3.4e+00
2.4e+00
2.0e+00
cases:6.98%
controls:2.32%
cases:9.18%
controls:1.33%
cases:5.70%
controls:0.16%
cases:1.90%
controls:0.00%
cases:4.56%
controls:0.16%
cases:11.46%
controls:1.16%
cases:23.50%
controls:3.89%
22
73
293
3077
29
42
287
3118
18
5
298
3155
6
0
310
3160
14
5
293
3149
33
36
255
3068
55
107
179
2647
Outpatient Visit
OP [9202]
8.0e-01
1.2e+00
1.5e+00
5.1e+00
1.8e+00
2.0e+00
1.9e+00
cases:82.22%
controls:67.56%
cases:75.63%
controls:47.34%
cases:34.49%
controls:10.22%
cases:37.66%
controls:0.38%
cases:41.04%
controls:10.02%
cases:87.15%
controls:48.23%
cases:95.30%
controls:75.67%
259
2128
56
1022
239
1496
77
1664
109
323
207
2837
119
12
197
3148
126
316
181
2838
251
1497
37
1607
223
2084
11
670
Physiotherapy
R4110 [2001310233]
9.6e-01
1.6e+00
2.6e+00
1.0e+50
3.3e+00
3.2e+00
2.3e+00
cases:9.84%
controls:4.00%
cases:10.44%
controls:2.22%
cases:2.85%
controls:0.22%
cases:11.08%
controls:0.00%
cases:9.77%
controls:0.38%
cases:27.78%
controls:1.58%
cases:32.05%
controls:4.32%
31
126
284
3024
33
70
283
3090
9
7
307
3153
35
0
281
3160
30
12
277
3142
80
49
208
3055
75
119
159
2635
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
1.2e+00
2.5e+00
2.9e+00
1.0e+50
3.5e+00
2.2e+00
1.5e+00
cases:8.57%
controls:2.63%
cases:8.54%
controls:0.73%
cases:3.80%
controls:0.22%
cases:2.85%
controls:0.00%
cases:5.21%
controls:0.16%
cases:10.76%
controls:1.35%
cases:14.10%
controls:3.45%
27
83
288
3067
27
23
289
3137
12
7
304
3153
9
0
307
3160
16
5
291
3149
31
42
257
3062
33
95
201
2659
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.0e+00
1.6e+00
3.2e+00
1.0e+50
3.8e+00
2.6e+00
1.6e+00
cases:10.79%
controls:4.19%
cases:8.23%
controls:1.84%
cases:4.43%
controls:0.19%
cases:2.85%
controls:0.00%
cases:6.84%
controls:0.16%
cases:22.22%
controls:2.09%
cases:28.63%
controls:7.52%
34
132
281
3018
26
58
290
3102
14
6
302
3154
9
0
307
3160
21
5
286
3149
64
65
224
3039
67
207
167
2547
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.9e+00
3.0e+00
3.1e+00
1.0e+50
—
3.1e+00
2.5e+00
cases:13.97%
controls:2.48%
cases:18.35%
controls:1.14%
cases:5.38%
controls:0.25%
cases:12.34%
controls:0.00%
—
—
cases:20.83%
controls:1.13%
cases:31.20%
controls:3.45%
44
78
271
3072
58
36
258
3124
17
8
299
3152
39
0
277
3160
—
60
35
228
3069
73
95
161
2659
Standard cardiac ultrasound examination
FM1AE [2001303278]
2.1e+00
3.5e+00
—
1.0e+50
—
4.3e+00
3.4e+00
cases:15.24%
controls:2.16%
cases:21.84%
controls:0.82%
—
—
cases:14.87%
controls:0.00%
—
—
cases:38.54%
controls:0.81%
cases:40.60%
controls:2.14%
48
68
267
3082
69
26
247
3134
—
47
0
269
3160
—
111
25
177
3079
95
59
139
2695
Internal Medicine
11 [38004456]
1.3e+00
2.3e+00
2.9e+00
—
3.1e+00
2.0e+00
1.7e+00
cases:47.30%
controls:19.14%
cases:42.09%
controls:6.80%
cases:18.35%
controls:1.20%
—
—
cases:17.26%
controls:0.92%
cases:37.50%
controls:7.64%
cases:50.43%
controls:15.98%
149
603
166
2547
133
215
183
2945
58
38
258
3122
—
53
29
254
3125
108
237
180
2867
118
440
116
2314
Atrial fibrillation and flutter
I48 [45596206]
1.6e+00
2.2e+00
2.7e+00
1.0e+50
2.7e+00
2.2e+00
1.6e+00
cases:19.37%
controls:4.54%
cases:18.04%
controls:2.31%
cases:7.59%
controls:0.54%
cases:8.54%
controls:0.00%
cases:7.17%
controls:0.51%
cases:20.14%
controls:2.64%
cases:23.93%
controls:6.03%
61
143
254
3007
57
73
259
3087
24
17
292
3143
27
0
289
3160
22
16
285
3138
58
82
230
3022
56
166
178
2588
Medical doctor
Z2221 [2001311556]
9.5e-01
1.9e+00
2.7e+00
1.0e+50
3.1e+00
2.5e+00
1.8e+00
cases:12.70%
controls:5.30%
cases:10.76%
controls:1.71%
cases:4.11%
controls:0.28%
cases:7.91%
controls:0.00%
cases:5.86%
controls:0.29%
cases:18.40%
controls:1.74%
cases:18.38%
controls:3.59%
40
167
275
2983
34
54
282
3106
13
9
303
3151
25
0
291
3160
18
9
289
3145
53
54
235
3050
43
99
191
2655
Office Visit
OMOP4822458 [581477]
1.0e+00
2.1e+00
2.5e+00
—
3.0e+00
2.7e+00
1.6e+00
cases:18.73%
controls:7.59%
cases:15.19%
controls:2.15%
cases:4.75%
controls:0.41%
—
—
cases:6.84%
controls:0.35%
cases:18.40%
controls:1.45%
cases:22.22%
controls:5.41%
59
239
256
2911
48
68
268
3092
15
13
301
3147
—
21
11
286
3143
53
45
235
3059
52
149
182
2605
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
1.1e+00
1.9e+00
2.8e+00
—
3.1e+00
2.1e+00
1.3e+00
cases:13.33%
controls:4.95%
cases:14.56%
controls:2.47%
cases:7.59%
controls:0.51%
—
—
cases:5.21%
controls:0.25%
cases:18.75%
controls:2.77%
cases:27.35%
controls:9.08%
42
156
273
2994
46
78
270
3082
24
16
292
3144
—
16
8
291
3146
54
86
234
3018
64
250
170
2504
Outpatient Hospital
22 [8756]
1.0e+00
1.8e+00
2.3e+00
—
3.0e+00
2.4e+00
1.6e+00
cases:43.81%
controls:22.32%
cases:33.54%
controls:7.56%
cases:11.08%
controls:1.23%
—
—
cases:15.96%
controls:0.92%
cases:41.67%
controls:6.15%
cases:50.85%
controls:16.74%
138
703
177
2447
106
239
210
2921
35
39
281
3121
—
49
29
258
3125
120
191
168
2913
119
461
115
2293
Rheumatology
66 [38004491]
1.6e+00
1.9e+00
2.5e+00
—
2.0e+00
2.2e+00
1.9e+00
cases:11.43%
controls:2.63%
cases:10.44%
controls:1.65%
cases:4.43%
controls:0.38%
—
—
cases:2.61%
controls:0.35%
cases:14.24%
controls:1.77%
cases:16.24%
controls:2.90%
36
83
279
3067
33
52
283
3108
14
12
302
3148
—
8
11
299
3143
41
55
247
3049
38
80
196
2674
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.4e+00
2.2e+00
—
—
3.3e+00
2.8e+00
2.2e+00
cases:10.79%
controls:2.98%
cases:11.08%
controls:1.42%
—
—
—
—
cases:4.89%
controls:0.19%
cases:20.14%
controls:1.55%
cases:30.34%
controls:4.68%
34
94
281
3056
35
45
281
3115
—
—
15
6
292
3148
58
48
230
3056
71
129
163
2625
INR in Blood by Coagulation assay
34714-6 [3032080]
1.1e+00
1.7e+00
2.2e+00
—
2.5e+00
2.2e+00
2.1e+00
cases:16.83%
controls:6.38%
cases:19.30%
controls:4.02%
cases:11.71%
controls:1.39%
—
—
cases:14.33%
controls:1.40%
cases:29.51%
controls:4.54%
cases:45.73%
controls:9.77%
53
201
262
2949
61
127
255
3033
37
44
279
3116
—
44
44
263
3110
85
141
203
2963
107
269
127
2485
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.4e-01
1.5e+00
2.9e+00
1.0e+50
3.5e+00
2.4e+00
1.6e+00
cases:6.98%
controls:3.81%
cases:8.86%
controls:2.18%
cases:4.75%
controls:0.28%
cases:3.48%
controls:0.00%
cases:7.49%
controls:0.25%
cases:15.28%
controls:1.68%
cases:22.22%
controls:5.41%
22
120
293
3030
28
69
288
3091
15
9
301
3151
11
0
305
3160
23
8
284
3146
44
52
244
3052
52
149
182
2605
Inpatient Hospital
21 [8717]
1.0e+00
2.0e+00
2.1e+00
—
2.9e+00
2.3e+00
1.4e+00
cases:52.70%
controls:28.51%
cases:43.67%
controls:9.75%
cases:12.34%
controls:1.77%
—
—
cases:19.22%
controls:1.33%
cases:48.96%
controls:9.09%
cases:52.99%
controls:21.79%
166
898
149
2252
138
308
178
2852
39
56
277
3104
—
59
42
248
3112
141
282
147
2822
124
600
110
2154
Heart failure, unspecified
I50.9 [45576879]
2.5e+00
3.7e+00
—
1.0e+50
—
3.3e+00
2.1e+00
cases:11.11%
controls:1.02%
cases:14.87%
controls:0.44%
—
—
cases:6.96%
controls:0.00%
—
—
cases:13.19%
controls:0.58%
cases:13.68%
controls:1.89%
35
32
280
3118
47
14
269
3146
—
22
0
294
3160
—
38
18
250
3086
32
52
202
2702
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.3e+00
1.9e+00
2.8e+00
—
2.9e+00
1.5e+00
1.1e+00
cases:7.62%
controls:2.25%
cases:9.49%
controls:1.58%
cases:4.11%
controls:0.25%
—
—
cases:3.26%
controls:0.19%
cases:7.64%
controls:1.84%
cases:13.68%
controls:4.79%
24
71
291
3079
30
50
286
3110
13
8
303
3152
—
10
6
297
3148
22
57
266
3047
32
132
202
2622
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
9.2e-01
1.9e+00
2.6e+00
—
2.4e+00
2.0e+00
1.5e+00
cases:10.16%
controls:4.32%
cases:12.97%
controls:2.15%
cases:3.80%
controls:0.28%
—
—
cases:4.89%
controls:0.44%
cases:20.14%
controls:3.41%
cases:35.04%
controls:10.31%
32
136
283
3014
41
68
275
3092
12
9
304
3151
—
15
14
292
3140
58
106
230
2998
82
284
152
2470
Doppler ultrasound examination of heart
FM1DE [2001303299]
2.2e+00
2.7e+00
—
1.0e+50
—
3.4e+00
3.2e+00
cases:6.35%
controls:0.76%
cases:4.75%
controls:0.35%
—
—
cases:2.53%
controls:0.00%
—
—
cases:8.68%
controls:0.32%
cases:11.54%
controls:0.54%
20
24
295
3126
15
11
301
3149
—
8
0
308
3160
—
25
10
263
3094
27
15
207
2739
potassium chloride; oral
A12BA01 [21600877]
2.6e+00
2.8e+00
—
—
—
3.2e+00
2.8e+00
cases:7.62%
controls:0.63%
cases:6.65%
controls:0.41%
—
—
—
—
—
—
cases:9.03%
controls:0.42%
cases:18.38%
controls:1.34%
24
20
291
3130
21
13
295
3147
—
—
—
26
13
262
3091
43
37
191
2717
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.2e-01
1.7e+00
2.4e+00
1.0e+50
2.9e+00
2.0e+00
1.6e+00
cases:14.92%
controls:7.14%
cases:19.30%
controls:4.34%
cases:9.81%
controls:0.98%
cases:4.11%
controls:0.00%
cases:12.38%
controls:0.79%
cases:27.08%
controls:4.99%
cases:40.60%
controls:11.66%
47
225
268
2925
61
137
255
3023
31
31
285
3129
13
0
303
3160
38
25
269
3129
78
155
210
2949
95
321
139
2433
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
9.8e-01
1.7e+00
2.5e+00
—
2.9e+00
1.8e+00
1.4e+00
cases:13.33%
controls:5.46%
cases:14.87%
controls:3.10%
cases:6.33%
controls:0.54%
—
—
cases:6.84%
controls:0.41%
cases:20.49%
controls:3.90%
cases:33.76%
controls:11.07%
42
172
273
2978
47
98
269
3062
20
17
296
3143
—
21
13
286
3141
59
121
229
2983
79
305
155
2449
enoxaparin; parenteral
B01AB05 [21600976]
1.3e+00
1.9e+00
1.8e+00
—
2.9e+00
1.9e+00
1.5e+00
cases:12.70%
controls:4.00%
cases:9.18%
controls:1.46%
cases:2.53%
controls:0.44%
—
—
cases:5.54%
controls:0.32%
cases:10.07%
controls:1.64%
cases:19.23%
controls:4.83%
40
126
275
3024
29
46
287
3114
8
14
308
3146
—
17
10
290
3144
29
51
259
3053
45
133
189
2621
diltiazem; oral
C08DB01 [21601771]
2.6e+00
2.4e+00
—
—
—
3.0e+00
3.2e+00
cases:3.17%
controls:0.25%
cases:2.85%
controls:0.25%
—
—
—
—
—
—
cases:4.51%
controls:0.23%
cases:7.69%
controls:0.33%
10
8
305
3142
9
8
307
3152
—
—
—
13
7
275
3097
18
9
216
2745
Hematology
82 [38004501]
1.9e+00
2.3e+00
2.3e+00
—
—
2.7e+00
1.9e+00
cases:5.40%
controls:0.83%
cases:4.75%
controls:0.47%
cases:2.53%
controls:0.25%
—
—
—
—
cases:5.90%
controls:0.42%
cases:6.84%
controls:1.05%
17
26
298
3124
15
15
301
3145
8
8
308
3152
—
—
17
13
271
3091
16
29
218
2725
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.1e-01
9.6e-01
1.8e+00
4.1e+00
2.4e+00
1.2e+00
6.8e-01
cases:29.52%
controls:21.68%
cases:30.70%
controls:14.53%
cases:17.09%
controls:3.16%
cases:13.61%
controls:0.25%
cases:21.50%
controls:2.50%
cases:37.15%
controls:15.34%
cases:52.56%
controls:35.88%
93
683
222
2467
97
459
219
2701
54
100
262
3060
43
8
273
3152
66
79
241
3075
107
476
181
2628
123
988
111
1766
Atherosclerotic heart disease
I25.1 [45596196]
9.4e-01
1.6e+00
2.2e+00
1.0e+50
2.8e+00
2.2e+00
1.2e+00
cases:9.52%
controls:3.94%
cases:8.54%
controls:1.80%
cases:3.16%
controls:0.35%
cases:6.33%
controls:0.00%
cases:5.21%
controls:0.32%
cases:13.19%
controls:1.74%
cases:13.68%
controls:4.39%
30
124
285
3026
27
57
289
3103
10
11
306
3149
20
0
296
3160
16
10
291
3144
38
54
250
3050
32
121
202
2633
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.4e-01
7.3e-01
2.1e+00
4.3e+00
2.1e+00
1.0e+00
6.0e-01
cases:22.86%
controls:17.37%
cases:25.63%
controls:14.27%
cases:20.89%
controls:3.10%
cases:12.03%
controls:0.19%
cases:19.87%
controls:3.01%
cases:33.33%
controls:15.05%
cases:44.02%
controls:30.07%
72
547
243
2603
81
451
235
2709
66
98
250
3062
38
6
278
3154
61
95
246
3059
96
467
192
2637
103
828
131
1926
Chronic kidney disease, unspecified
N18.9 [45553438]
2.6e+00
2.8e+00
—
—
—
3.2e+00
2.2e+00
cases:4.13%
controls:0.32%
cases:2.53%
controls:0.16%
—
—
—
—
—
—
cases:5.21%
controls:0.23%
cases:6.41%
controls:0.73%
13
10
302
3140
8
5
308
3155
—
—
—
15
7
273
3097
15
20
219
2734
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
7.9e-01
2.0e+00
4.4e+00
2.1e+00
9.2e-01
5.3e-01
cases:30.48%
controls:25.56%
cases:33.86%
controls:18.89%
cases:23.73%
controls:3.89%
cases:15.82%
controls:0.22%
cases:21.82%
controls:3.39%
cases:40.28%
controls:21.17%
cases:55.56%
controls:42.45%
96
805
219
2345
107
597
209
2563
75
123
241
3037
50
7
266
3153
67
107
240
3047
116
657
172
2447
130
1169
104
1585
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.3e-01
7.9e-01
2.0e+00
4.4e+00
2.1e+00
9.2e-01
5.1e-01
cases:30.48%
controls:25.75%
cases:34.18%
controls:19.08%
cases:24.05%
controls:3.92%
cases:15.51%
controls:0.22%
cases:22.15%
controls:3.46%
cases:40.28%
controls:21.26%
cases:55.56%
controls:42.81%
96
811
219
2339
108
603
208
2557
76
124
240
3036
49
7
267
3153
68
109
239
3045
116
660
172
2444
130
1179
104
1575
amlodipine; oral
C08CA01 [21601747]
2.1e+00
2.1e+00
1.7e+00
—
2.0e+00
1.8e+00
1.1e+00
cases:17.14%
controls:2.57%
cases:16.14%
controls:2.31%
cases:5.06%
controls:0.95%
—
—
cases:4.56%
controls:0.67%
cases:13.54%
controls:2.55%
cases:14.10%
controls:5.08%
54
81
261
3069
51
73
265
3087
16
30
300
3130
—
14
21
293
3133
39
79
249
3025
33
140
201
2614
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.2e+00
1.7e+00
2.1e+00
—
2.5e+00
1.7e+00
1.5e+00
cases:13.02%
controls:4.25%
cases:13.29%
controls:2.69%
cases:5.38%
controls:0.70%
—
—
cases:7.49%
controls:0.67%
cases:16.32%
controls:3.29%
cases:24.79%
controls:7.01%
41
134
274
3016
42
85
274
3075
17
22
299
3138
—
23
21
284
3133
47
102
241
3002
58
193
176
2561
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
2.4e+00
2.6e+00
1.0e+50
1.0e+50
—
3.0e+00
2.7e+00
cases:8.25%
controls:0.79%
cases:6.01%
controls:0.47%
cases:3.80%
controls:0.00%
cases:3.16%
controls:0.00%
—
—
cases:9.72%
controls:0.52%
cases:16.67%
controls:1.34%
26
25
289
3125
19
15
297
3145
12
0
304
3160
10
0
306
3160
—
28
16
260
3088
39
37
195
2717
Bacteria identified in Blood by Culture
600-7 [3023368]
8.9e-01
1.5e+00
2.7e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:6.35%
controls:2.70%
cases:7.28%
controls:1.71%
cases:3.16%
controls:0.22%
—
—
cases:3.58%
controls:0.25%
cases:8.33%
controls:1.68%
cases:15.81%
controls:5.30%
20
85
295
3065
23
54
293
3106
10
7
306
3153
—
11
8
296
3146
24
52
264
3052
37
146
197
2608
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.1e+00
1.6e+00
2.3e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:18.73%
controls:7.30%
cases:19.94%
controls:4.84%
cases:9.18%
controls:0.98%
—
—
cases:11.73%
controls:0.89%
cases:24.31%
controls:5.32%
cases:33.76%
controls:13.14%
59
230
256
2920
63
153
253
3007
29
31
287
3129
—
36
28
271
3126
70
165
218
2939
79
362
155
2392
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.2e+00
2.1e+00
—
—
3.1e+00
2.4e+00
1.9e+00
cases:7.62%
controls:2.54%
cases:10.13%
controls:1.33%
—
—
—
—
cases:3.91%
controls:0.19%
cases:17.71%
controls:1.93%
cases:30.34%
controls:6.14%
24
80
291
3070
32
42
284
3118
—
—
12
6
295
3148
51
60
237
3044
71
169
163
2585
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.0e+00
1.6e+00
2.4e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:17.14%
controls:6.86%
cases:19.30%
controls:4.62%
cases:8.86%
controls:0.89%
—
—
cases:11.40%
controls:0.89%
cases:23.26%
controls:5.12%
cases:32.48%
controls:12.78%
54
216
261
2934
61
146
255
3014
28
28
288
3132
—
35
28
272
3126
67
159
221
2945
76
352
158
2402
Basophils [#/volume] in Blood
26444-0 [3006315]
1.0e+00
1.6e+00
2.4e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:17.14%
controls:6.92%
cases:19.30%
controls:4.65%
cases:8.86%
controls:0.89%
—
—
cases:11.40%
controls:0.89%
cases:23.26%
controls:5.15%
cases:32.48%
controls:12.82%
54
218
261
2932
61
147
255
3013
28
28
288
3132
—
35
28
272
3126
67
160
221
2944
76
353
158
2401
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.0e+00
1.6e+00
2.4e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:18.10%
controls:7.37%
cases:19.94%
controls:4.97%
cases:9.49%
controls:0.92%
—
—
cases:11.73%
controls:0.92%
cases:23.26%
controls:5.41%
cases:33.76%
controls:13.36%
57
232
258
2918
63
157
253
3003
30
29
286
3131
—
36
29
271
3125
67
168
221
2936
79
368
155
2386
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.0e+00
1.6e+00
2.2e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:15.87%
controls:6.48%
cases:18.04%
controls:4.34%
cases:8.23%
controls:0.95%
—
—
cases:10.42%
controls:0.79%
cases:21.88%
controls:4.74%
cases:31.20%
controls:11.62%
50
204
265
2946
57
137
259
3023
26
30
290
3130
—
32
25
275
3129
63
147
225
2957
73
320
161
2434
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
1.9e+00
2.3e+00
2.5e+00
1.0e+50
—
2.3e+00
1.5e+00
cases:13.65%
controls:2.22%
cases:9.49%
controls:1.08%
cases:2.53%
controls:0.22%
cases:4.75%
controls:0.00%
—
—
cases:11.11%
controls:1.22%
cases:14.96%
controls:3.85%
43
70
272
3080
30
34
286
3126
8
7
308
3153
15
0
301
3160
—
32
38
256
3066
35
106
199
2648
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.0e+00
1.6e+00
2.2e+00
—
2.6e+00
1.7e+00
1.3e+00
cases:15.87%
controls:6.51%
cases:18.04%
controls:4.37%
cases:8.23%
controls:0.95%
—
—
cases:10.42%
controls:0.82%
cases:21.88%
controls:4.74%
cases:31.62%
controls:11.69%
50
205
265
2945
57
138
259
3022
26
30
290
3130
—
32
26
275
3128
63
147
225
2957
74
322
160
2432
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
9.8e-01
1.6e+00
2.3e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:16.51%
controls:6.89%
cases:18.35%
controls:4.53%
cases:8.23%
controls:0.92%
—
—
cases:10.75%
controls:0.82%
cases:21.88%
controls:4.93%
cases:32.48%
controls:12.24%
52
217
263
2933
58
143
258
3017
26
29
290
3131
—
33
26
274
3128
63
153
225
2951
76
337
158
2417
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.9e-01
1.6e+00
2.2e+00
—
2.6e+00
1.7e+00
1.2e+00
cases:15.87%
controls:6.54%
cases:18.04%
controls:4.37%
cases:8.23%
controls:0.95%
—
—
cases:10.42%
controls:0.82%
cases:21.88%
controls:4.80%
cases:31.20%
controls:11.62%
50
206
265
2944
57
138
259
3022
26
30
290
3130
—
32
26
275
3128
63
149
225
2955
73
320
161
2434
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.5e+00
2.2e+00
—
—
3.3e+00
2.1e+00
1.3e+00
cases:5.71%
controls:1.30%
cases:6.33%
controls:0.76%
—
—
—
—
cases:4.23%
controls:0.16%
cases:7.29%
controls:1.00%
cases:6.41%
controls:1.82%
18
41
297
3109
20
24
296
3136
—
—
13
5
294
3149
21
31
267
3073
15
50
219
2704
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
9.2e-01
1.6e+00
2.3e+00
—
2.7e+00
1.7e+00
1.2e+00
cases:14.92%
controls:6.51%
cases:18.04%
controls:4.37%
cases:7.91%
controls:0.89%
—
—
cases:10.42%
controls:0.79%
cases:21.53%
controls:4.77%
cases:31.62%
controls:11.87%
47
205
268
2945
57
138
259
3022
25
28
291
3132
—
32
25
275
3129
62
148
226
2956
74
327
160
2427
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
1.7e+00
2.4e+00
—
—
—
3.4e+00
2.8e+00
cases:6.35%
controls:1.24%
cases:4.75%
controls:0.44%
—
—
—
—
—
—
cases:6.25%
controls:0.23%
cases:10.68%
controls:0.73%
20
39
295
3111
15
14
301
3146
—
—
—
18
7
270
3097
25
20
209
2734
Emergency Room Visit
ER [9203]
8.5e-01
1.9e+00
2.4e+00
—
2.2e+00
1.7e+00
1.2e+00
cases:51.11%
controls:30.95%
cases:43.67%
controls:10.70%
cases:15.82%
controls:1.65%
—
—
cases:10.42%
controls:1.27%
cases:38.19%
controls:10.05%
cases:54.70%
controls:26.62%
161
975
154
2175
138
338
178
2822
50
52
266
3108
—
32
40
275
3114
110
312
178
2792
128
733
106
2021
CBC panel - Blood by Automated count
58410-2 [40761511]
2.6e-01
6.9e-01
1.7e+00
4.4e+00
1.8e+00
9.4e-01
5.3e-01
cases:30.48%
controls:25.17%
cases:29.75%
controls:17.56%
cases:17.41%
controls:3.64%
cases:11.71%
controls:0.16%
cases:15.31%
controls:2.79%
cases:35.07%
controls:17.46%
cases:49.57%
controls:36.75%
96
793
219
2357
94
555
222
2605
55
115
261
3045
37
5
279
3155
47
88
260
3066
101
542
187
2562
116
1012
118
1742
FEV1
20150-9 [3024653]
1.6e+00
2.9e+00
—
—
—
2.9e+00
2.7e+00
cases:7.94%
controls:1.71%
cases:8.23%
controls:0.51%
—
—
—
—
—
—
cases:11.46%
controls:0.71%
cases:13.25%
controls:1.02%
25
54
290
3096
26
16
290
3144
—
—
—
33
22
255
3082
31
28
203
2726
FEV1/FVC
19926-5 [3011505]
1.6e+00
2.9e+00
—
—
—
2.9e+00
2.7e+00
cases:7.94%
controls:1.71%
cases:8.23%
controls:0.51%
—
—
—
—
—
—
cases:11.46%
controls:0.71%
cases:13.25%
controls:1.02%
25
54
290
3096
26
16
290
3144
—
—
—
33
22
255
3082
31
28
203
2726
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.6e+00
2.9e+00
—
—
—
2.9e+00
2.7e+00
cases:7.94%
controls:1.71%
cases:8.23%
controls:0.51%
—
—
—
—
—
—
cases:11.46%
controls:0.71%
cases:13.25%
controls:1.02%
25
54
290
3096
26
16
290
3144
—
—
—
33
22
255
3082
31
28
203
2726
Thrombin time
3243-3 [3036489]
1.4e+00
3.3e+00
—
1.0e+50
—
3.9e+00
2.9e+00
cases:2.22%
controls:0.57%
cases:4.11%
controls:0.16%
—
—
cases:1.58%
controls:0.00%
—
—
cases:8.68%
controls:0.19%
cases:7.69%
controls:0.47%
7
18
308
3132
13
5
303
3155
—
5
0
311
3160
—
25
6
263
3098
18
13
216
2741
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.6e+00
2.8e+00
1.0e+50
—
—
2.9e+00
2.7e+00
cases:7.30%
controls:1.56%
cases:7.59%
controls:0.47%
cases:2.22%
controls:0.00%
—
—
—
—
cases:10.42%
controls:0.61%
cases:11.97%
controls:0.94%
23
49
292
3101
24
15
292
3145
7
0
309
3160
—
—
30
19
258
3085
28
26
206
2728
FEV1 percent change
69983-5 [42868472]
1.6e+00
2.8e+00
1.0e+50
—
—
2.9e+00
2.7e+00
cases:7.30%
controls:1.56%
cases:7.59%
controls:0.47%
cases:2.22%
controls:0.00%
—
—
—
—
cases:10.42%
controls:0.61%
cases:11.97%
controls:0.94%
23
49
292
3101
24
15
292
3145
7
0
309
3160
—
—
30
19
258
3085
28
26
206
2728
FEV1 --post bronchodilation
20155-8 [3023550]
1.6e+00
2.8e+00
1.0e+50
—
—
2.9e+00
2.7e+00
cases:7.30%
controls:1.56%
cases:7.59%
controls:0.47%
cases:2.22%
controls:0.00%
—
—
—
—
cases:10.42%
controls:0.61%
cases:11.97%
controls:0.94%
23
49
292
3101
24
15
292
3145
7
0
309
3160
—
—
30
19
258
3085
28
26
206
2728
FVC percent change Respiratory system
69982-7 [42868471]
1.6e+00
2.8e+00
1.0e+50
—
—
2.9e+00
2.7e+00
cases:7.30%
controls:1.56%
cases:7.59%
controls:0.47%
cases:2.22%
controls:0.00%
—
—
—
—
cases:10.42%
controls:0.61%
cases:11.97%
controls:0.94%
23
49
292
3101
24
15
292
3145
7
0
309
3160
—
—
30
19
258
3085
28
26
206
2728
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.6e+00
2.8e+00
1.0e+50
—
—
2.9e+00
2.7e+00
cases:7.30%
controls:1.56%
cases:7.59%
controls:0.47%
cases:2.22%
controls:0.00%
—
—
—
—
cases:10.42%
controls:0.61%
cases:11.97%
controls:0.94%
23
49
292
3101
24
15
292
3145
7
0
309
3160
—
—
30
19
258
3085
28
26
206
2728
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
4.2e-01
1.5e+00
2.5e+00
—
2.5e+00
2.1e+00
1.5e+00
cases:5.08%
controls:3.40%
cases:5.70%
controls:1.39%
cases:2.22%
controls:0.19%
—
—
cases:2.28%
controls:0.19%
cases:7.99%
controls:1.06%
cases:16.67%
controls:4.39%
16
107
299
3043
18
44
298
3116
7
6
309
3154
—
7
6
300
3148
23
33
265
3071
39
121
195
2633
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
1.9e+00
2.6e+00
—
—
—
2.9e+00
2.6e+00
cases:2.54%
controls:0.38%
cases:2.85%
controls:0.22%
—
—
—
—
—
—
cases:2.78%
controls:0.16%
cases:3.85%
controls:0.29%
8
12
307
3138
9
7
307
3153
—
—
—
8
5
280
3099
9
8
225
2746
allopurinol; oral, parenteral
M04AA01 [21604131]
2.2e+00
2.7e+00
—
—
—
2.8e+00
2.3e+00
cases:8.89%
controls:1.11%
cases:8.54%
controls:0.60%
—
—
—
—
—
—
cases:10.07%
controls:0.68%
cases:12.39%
controls:1.42%
28
35
287
3115
27
19
289
3141
—
—
—
29
21
259
3083
29
39
205
2715
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
6.7e-01
1.3e+00
2.2e+00
—
3.0e+00
1.6e+00
1.1e+00
cases:22.54%
controls:12.98%
cases:22.15%
controls:6.96%
cases:8.86%
controls:1.08%
—
—
cases:11.40%
controls:0.67%
cases:28.47%
controls:7.41%
cases:42.74%
controls:20.59%
71
409
244
2741
70
220
246
2940
28
34
288
3126
—
35
21
272
3133
82
230
206
2874
100
567
134
2187
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.8e+00
2.6e+00
—
—
—
2.9e+00
2.5e+00
cases:6.35%
controls:1.14%
cases:7.59%
controls:0.60%
—
—
—
—
—
—
cases:14.93%
controls:0.97%
cases:27.35%
controls:3.01%
20
36
295
3114
24
19
292
3141
—
—
—
43
30
245
3074
64
83
170
2671
Dyspnoea
R06.0 [45558449]
2.1e+00
3.6e+00
—
1.0e+50
—
2.5e+00
1.6e+00
cases:18.10%
controls:2.76%
cases:19.62%
controls:0.70%
—
—
cases:4.75%
controls:0.00%
—
—
cases:10.42%
controls:0.97%
cases:14.53%
controls:3.41%
57
87
258
3063
62
22
254
3138
—
15
0
301
3160
—
30
30
258
3074
34
94
200
2660
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.6e-01
6.8e-01
1.8e+00
3.7e+00
1.9e+00
8.9e-01
5.4e-01
cases:21.90%
controls:17.71%
cases:25.00%
controls:14.49%
cases:16.46%
controls:3.13%
cases:7.28%
controls:0.19%
cases:17.59%
controls:2.98%
cases:32.29%
controls:16.37%
cases:44.87%
controls:32.21%
69
558
246
2592
79
458
237
2702
52
99
264
3061
23
6
293
3154
54
94
253
3060
93
508
195
2596
105
887
129
1867
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.7e+00
2.5e+00
—
—
—
2.9e+00
2.4e+00
cases:5.71%
controls:1.11%
cases:6.33%
controls:0.54%
—
—
—
—
—
—
cases:12.85%
controls:0.81%
cases:23.08%
controls:2.54%
18
35
297
3115
20
17
296
3143
—
—
—
37
25
251
3079
54
70
180
2684
tiotropium bromide; inhalant
R03BB04 [21603296]
1.8e+00
2.1e+00
—
—
2.2e+00
2.1e+00
1.3e+00
cases:8.57%
controls:1.49%
cases:8.23%
controls:1.11%
—
—
—
—
cases:3.91%
controls:0.44%
cases:9.03%
controls:1.16%
cases:7.26%
controls:2.11%
27
47
288
3103
26
35
290
3125
—
—
12
14
295
3140
26
36
262
3068
17
58
217
2696
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.7e-01
1.3e+00
2.3e+00
—
3.2e+00
1.7e+00
1.1e+00
cases:6.35%
controls:3.68%
cases:7.59%
controls:2.18%
cases:2.85%
controls:0.28%
—
—
cases:3.58%
controls:0.16%
cases:9.38%
controls:1.90%
cases:17.52%
controls:6.90%
20
116
295
3034
24
69
292
3091
9
9
307
3151
—
11
5
296
3149
27
59
261
3045
41
190
193
2564
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
1.5e+00
3.1e+00
—
—
—
3.2e+00
1.6e+00
cases:11.11%
controls:2.67%
cases:10.44%
controls:0.51%
—
—
—
—
—
—
cases:9.03%
controls:0.39%
cases:8.97%
controls:1.96%
35
84
280
3066
33
16
283
3144
—
—
—
26
12
262
3092
21
54
213
2700
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.5e-01
6.5e-01
1.9e+00
4.2e+00
1.9e+00
8.4e-01
4.0e-01
cases:30.79%
controls:27.68%
cases:35.13%
controls:22.09%
cases:25.32%
controls:4.72%
cases:15.82%
controls:0.28%
cases:24.10%
controls:4.63%
cases:41.67%
controls:23.65%
cases:55.98%
controls:46.01%
97
872
218
2278
111
698
205
2462
80
149
236
3011
50
9
266
3151
74
146
233
3008
120
734
168
2370
131
1267
103
1487
ECG with 12 standard connections
XF400 [2001303368]
7.7e-01
2.4e+00
2.5e+00
1.0e+50
—
2.2e+00
2.3e+00
cases:3.81%
controls:1.81%
cases:5.06%
controls:0.47%
cases:2.22%
controls:0.19%
cases:1.90%
controls:0.00%
—
—
cases:3.82%
controls:0.42%
cases:10.26%
controls:1.13%
12
57
303
3093
16
15
300
3145
7
6
309
3154
6
0
310
3160
—
11
13
277
3091
24
31
210
2723
prednisolone
A07EA01 [21600653]
1.3e+00
1.5e+00
1.4e+00
—
2.1e+00
1.7e+00
1.4e+00
cases:24.44%
controls:8.44%
cases:15.82%
controls:3.86%
cases:4.11%
controls:1.08%
—
—
cases:5.54%
controls:0.73%
cases:21.18%
controls:4.51%
cases:30.34%
controls:9.62%
77
266
238
2884
50
122
266
3038
13
34
303
3126
—
17
23
290
3131
61
140
227
2964
71
265
163
2489
prednisolone; oral, parenteral
H02AB06 [21602734]
1.3e+00
1.5e+00
1.4e+00
—
2.1e+00
1.7e+00
1.4e+00
cases:24.44%
controls:8.41%
cases:15.82%
controls:3.86%
cases:4.11%
controls:1.08%
—
—
cases:5.54%
controls:0.73%
cases:21.18%
controls:4.48%
cases:29.91%
controls:9.55%
77
265
238
2885
50
122
266
3038
13
34
303
3126
—
17
23
290
3131
61
139
227
2965
70
263
164
2491
Pneumonia, unspecified
J18.9 [45601123]
1.2e+00
2.3e+00
2.8e+00
1.0e+50
—
2.0e+00
1.1e+00
cases:8.89%
controls:2.98%
cases:7.28%
controls:0.79%
cases:3.16%
controls:0.19%
cases:1.58%
controls:0.00%
—
—
cases:7.99%
controls:1.16%
cases:12.39%
controls:4.47%
28
94
287
3056
23
25
293
3135
10
6
306
3154
5
0
311
3160
—
23
36
265
3068
29
123
205
2631
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.6e+00
2.4e+00
—
—
—
2.9e+00
2.5e+00
cases:5.71%
controls:1.21%
cases:6.01%
controls:0.60%
—
—
—
—
—
—
cases:12.50%
controls:0.81%
cases:23.50%
controls:2.58%
18
38
297
3112
19
19
297
3141
—
—
—
36
25
252
3079
55
71
179
2683
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
1.3e+00
2.5e+00
—
—
—
3.1e+00
3.7e+00
cases:2.22%
controls:0.60%
cases:2.22%
controls:0.19%
—
—
—
—
—
—
cases:3.47%
controls:0.16%
cases:8.97%
controls:0.25%
7
19
308
3131
7
6
309
3154
—
—
—
10
5
278
3099
21
7
213
2747
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.5e-01
1.3e+00
2.1e+00
—
2.3e+00
1.6e+00
1.2e+00
cases:17.78%
controls:8.44%
cases:19.62%
controls:6.46%
cases:10.76%
controls:1.49%
—
—
cases:12.70%
controls:1.49%
cases:24.65%
controls:6.48%
cases:35.90%
controls:14.63%
56
266
259
2884
62
204
254
2956
34
47
282
3113
—
39
47
268
3107
71
201
217
2903
84
403
150
2351
Bacteria [Presence] in Urine
87829-8 [36304419]
5.5e-01
1.2e+00
2.1e+00
—
3.1e+00
1.7e+00
1.1e+00
cases:6.35%
controls:3.78%
cases:7.28%
controls:2.22%
cases:2.22%
controls:0.28%
—
—
cases:3.91%
controls:0.19%
cases:9.72%
controls:1.90%
cases:16.67%
controls:6.43%
20
119
295
3031
23
70
293
3090
7
9
309
3151
—
12
6
295
3148
28
59
260
3045
39
177
195
2577
Normoblasts [#/volume] in Blood
715-3 [3021589]
8.5e-01
1.1e+00
1.9e+00
—
2.5e+00
1.5e+00
1.3e+00
cases:12.38%
controls:5.68%
cases:14.56%
controls:5.19%
cases:8.23%
controls:1.27%
—
—
cases:12.05%
controls:1.14%
cases:21.18%
controls:5.73%
cases:29.49%
controls:10.60%
39
179
276
2971
46
164
270
2996
26
40
290
3120
—
37
36
270
3118
61
178
227
2926
69
292
165
2462
Flexible bronchoscopy
UGC12 [2001303610]
1.8e+00
2.6e+00
—
—
—
2.4e+00
2.4e+00
cases:2.86%
controls:0.51%
cases:2.53%
controls:0.19%
—
—
—
—
—
—
cases:1.74%
controls:0.16%
cases:5.98%
controls:0.58%
9
16
306
3134
8
6
308
3154
—
—
—
5
5
283
3099
14
16
220
2738
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
2.9e+00
—
—
1.0e+50
—
3.3e+00
3.0e+00
cases:7.30%
controls:0.44%
—
—
—
—
cases:3.48%
controls:0.00%
—
—
cases:9.38%
controls:0.39%
cases:13.25%
controls:0.76%
23
14
292
3136
—
—
11
0
305
3160
—
27
12
261
3092
31
21
203
2733
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.0e-01
1.3e+00
2.1e+00
—
2.4e+00
1.6e+00
1.2e+00
cases:20.95%
controls:13.90%
cases:26.27%
controls:8.80%
cases:13.29%
controls:1.84%
—
—
cases:15.64%
controls:1.59%
cases:33.68%
controls:9.41%
cases:47.86%
controls:22.19%
66
438
249
2712
83
278
233
2882
42
58
274
3102
—
48
50
259
3104
97
292
191
2812
112
611
122
2143
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
6.1e-01
1.2e+00
2.3e+00
—
3.1e+00
1.4e+00
1.1e+00
cases:6.35%
controls:3.56%
cases:5.38%
controls:1.61%
cases:1.90%
controls:0.19%
—
—
cases:3.26%
controls:0.16%
cases:5.90%
controls:1.55%
cases:15.38%
controls:5.92%
20
112
295
3038
17
51
299
3109
6
6
310
3154
—
10
5
297
3149
17
48
271
3056
36
163
198
2591
EKG study
11524-6 [3013512]
5.3e-01
1.2e+00
3.2e+00
1.0e+50
2.4e+00
1.5e+00
7.4e-01
cases:7.62%
controls:4.63%
cases:8.86%
controls:2.78%
cases:6.01%
controls:0.25%
cases:1.58%
controls:0.00%
cases:4.56%
controls:0.44%
cases:10.07%
controls:2.55%
cases:16.24%
controls:8.50%
24
146
291
3004
28
88
288
3072
19
8
297
3152
5
0
311
3160
14
14
293
3140
29
79
259
3025
38
234
196
2520
Asthma, unspecified
J45.9 [45562456]
1.2e+00
2.1e+00
1.8e+00
1.0e+50
2.3e+00
2.0e+00
1.3e+00
cases:6.98%
controls:2.13%
cases:8.86%
controls:1.14%
cases:1.58%
controls:0.25%
cases:1.90%
controls:0.00%
cases:2.28%
controls:0.22%
cases:7.29%
controls:1.06%
cases:10.26%
controls:3.05%
22
67
293
3083
28
36
288
3124
5
8
311
3152
6
0
310
3160
7
7
300
3147
21
33
267
3071
24
84
210
2670
12 lead EKG panel
34534-8 [3044889]
6.1e-01
1.2e+00
2.4e+00
—
2.3e+00
1.3e+00
1.1e+00
cases:21.90%
controls:13.27%
cases:20.89%
controls:7.22%
cases:8.86%
controls:0.89%
—
—
cases:6.84%
controls:0.70%
cases:23.26%
controls:7.54%
cases:42.31%
controls:20.01%
69
418
246
2732
66
228
250
2932
28
28
288
3132
—
21
22
286
3132
67
234
221
2870
99
551
135
2203
felodipine; oral
C08CA02 [21601748]
2.0e+00
2.4e+00
—
—
—
2.1e+00
2.2e+00
cases:2.86%
controls:0.38%
cases:2.85%
controls:0.25%
—
—
—
—
—
—
cases:2.43%
controls:0.29%
cases:4.27%
controls:0.47%
9
12
306
3138
9
8
307
3152
—
—
—
7
9
281
3095
10
13
224
2741
pH of Serum or Plasma
2753-2 [3018418]
7.8e-01
1.2e+00
2.4e+00
—
2.1e+00
1.2e+00
1.2e+00
cases:7.94%
controls:3.81%
cases:7.91%
controls:2.53%
cases:3.48%
controls:0.32%
—
—
cases:1.95%
controls:0.25%
cases:7.99%
controls:2.61%
cases:18.80%
controls:6.64%
25
120
290
3030
25
80
291
3080
11
10
305
3150
—
6
8
301
3146
23
81
265
3023
44
183
190
2571
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.5e-01
5.4e-01
1.8e+00
4.1e+00
1.7e+00
6.7e-01
2.9e-01
cases:32.70%
controls:29.52%
cases:36.08%
controls:24.78%
cases:27.22%
controls:5.73%
cases:16.77%
controls:0.35%
cases:23.78%
controls:5.33%
cases:40.97%
controls:26.16%
cases:56.41%
controls:49.31%
103
930
212
2220
114
783
202
2377
86
181
230
2979
53
11
263
3149
73
168
234
2986
118
812
170
2292
132
1358
102
1396
MCH [Entitic mass]
28539-5 [3035941]
1.5e-01
5.4e-01
1.8e+00
4.0e+00
1.7e+00
6.7e-01
2.9e-01
cases:32.70%
controls:29.46%
cases:36.08%
controls:24.75%
cases:27.22%
controls:5.70%
cases:16.46%
controls:0.35%
cases:23.78%
controls:5.29%
cases:40.97%
controls:26.13%
cases:56.41%
controls:49.24%
103
928
212
2222
114
782
202
2378
86
180
230
2980
52
11
264
3149
73
167
234
2987
118
811
170
2293
132
1356
102
1398
Platelets [#/volume] in Blood
26515-7 [3007461]
1.4e-01
5.4e-01
1.8e+00
4.0e+00
1.7e+00
6.7e-01
2.9e-01
cases:32.38%
controls:29.37%
cases:36.08%
controls:24.68%
cases:27.22%
controls:5.70%
cases:16.46%
controls:0.35%
cases:23.78%
controls:5.33%
cases:40.97%
controls:26.16%
cases:56.41%
controls:49.27%
102
925
213
2225
114
780
202
2380
86
180
230
2980
52
11
264
3149
73
168
234
2986
118
812
170
2292
132
1357
102
1397
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.5e-01
5.4e-01
1.8e+00
4.0e+00
1.7e+00
6.8e-01
2.8e-01
cases:32.70%
controls:29.59%
cases:36.08%
controls:24.81%
cases:27.22%
controls:5.76%
cases:16.46%
controls:0.35%
cases:23.78%
controls:5.29%
cases:41.32%
controls:26.22%
cases:56.41%
controls:49.35%
103
932
212
2218
114
784
202
2376
86
182
230
2978
52
11
264
3149
73
167
234
2987
119
814
169
2290
132
1359
102
1395
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.5e-01
5.4e-01
1.8e+00
4.0e+00
1.7e+00
6.7e-01
2.8e-01
cases:32.70%
controls:29.52%
cases:36.08%
controls:24.78%
cases:27.22%
controls:5.70%
cases:16.46%
controls:0.35%
cases:23.78%
controls:5.33%
cases:40.97%
controls:26.16%
cases:56.41%
controls:49.35%
103
930
212
2220
114
783
202
2377
86
180
230
2980
52
11
264
3149
73
168
234
2986
118
812
170
2292
132
1359
102
1395
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
4.3e-01
1.3e+00
2.0e+00
—
2.7e+00
1.7e+00
1.0e+00
cases:6.35%
controls:4.22%
cases:8.54%
controls:2.44%
cases:2.85%
controls:0.38%
—
—
cases:3.58%
controls:0.25%
cases:11.11%
controls:2.16%
cases:18.80%
controls:7.81%
20
133
295
3017
27
77
289
3083
9
12
307
3148
—
11
8
296
3146
32
67
256
3037
44
215
190
2539
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.5e-01
5.3e-01
1.8e+00
4.0e+00
1.7e+00
6.7e-01
2.8e-01
cases:32.70%
controls:29.52%
cases:36.08%
controls:24.84%
cases:27.22%
controls:5.82%
cases:16.46%
controls:0.35%
cases:24.43%
controls:5.36%
cases:40.97%
controls:26.22%
cases:56.41%
controls:49.35%
103
930
212
2220
114
785
202
2375
86
184
230
2976
52
11
264
3149
75
169
232
2985
118
814
170
2290
132
1359
102
1395
High resolution CT examination of lungs
GD1DD [2001303632]
3.0e+00
3.3e+00
—
—
—
—
2.5e+00
cases:4.76%
controls:0.25%
cases:5.06%
controls:0.19%
—
—
—
—
—
—
—
—
cases:6.41%
controls:0.58%
15
8
300
3142
16
6
300
3154
—
—
—
—
15
16
219
2738
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.5e-01
5.4e-01
1.8e+00
4.0e+00
1.7e+00
6.7e-01
2.9e-01
cases:32.70%
controls:29.52%
cases:36.08%
controls:24.81%
cases:27.22%
controls:5.76%
cases:16.46%
controls:0.35%
cases:23.78%
controls:5.33%
cases:40.97%
controls:26.19%
cases:56.41%
controls:49.31%
103
930
212
2220
114
784
202
2376
86
182
230
2978
52
11
264
3149
73
168
234
2986
118
813
170
2291
132
1358
102
1396
Supplier / Service Provider
OMOP5117446 [33004]
-4.7e-01
2.1e-01
1.4e+00
—
—
3.5e+00
3.8e+00
cases:16.83%
controls:24.44%
cases:11.08%
controls:9.21%
cases:3.48%
controls:0.85%
—
—
—
—
cases:19.79%
controls:0.71%
cases:31.20%
controls:1.02%
53
770
262
2380
35
291
281
2869
11
27
305
3133
—
—
57
22
231
3082
73
28
161
2726
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
8.7e-01
1.3e+00
1.9e+00
—
2.3e+00
1.4e+00
1.0e+00
cases:11.11%
controls:4.98%
cases:6.65%
controls:1.87%
cases:2.22%
controls:0.35%
—
—
cases:3.26%
controls:0.35%
cases:8.68%
controls:2.26%
cases:15.81%
controls:6.32%
35
157
280
2993
21
59
295
3101
7
11
309
3149
—
10
11
297
3143
25
70
263
3034
37
174
197
2580
lercanidipine; oral
C08CA13 [21601759]
2.4e+00
2.5e+00
2.0e+00
—
—
2.1e+00
1.7e+00
cases:5.40%
controls:0.51%
cases:5.38%
controls:0.44%
cases:1.58%
controls:0.22%
—
—
—
—
cases:4.17%
controls:0.52%
cases:5.13%
controls:1.02%
17
16
298
3134
17
14
299
3146
5
7
311
3153
—
—
12
16
276
3088
12
28
222
2726
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.9e-01
1.4e+00
2.1e+00
—
2.6e+00
1.6e+00
9.7e-01
cases:8.57%
controls:5.43%
cases:10.13%
controls:2.78%
cases:3.16%
controls:0.38%
—
—
cases:4.23%
controls:0.32%
cases:11.11%
controls:2.55%
cases:20.51%
controls:8.90%
27
171
288
2979
32
88
284
3072
10
12
306
3148
—
13
10
294
3144
32
79
256
3025
48
245
186
2509
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.3e+00
2.7e+00
—
1.0e+50
—
2.7e+00
1.9e+00
cases:3.49%
controls:0.95%
cases:6.33%
controls:0.44%
—
—
cases:3.48%
controls:0.00%
—
—
cases:6.94%
controls:0.52%
cases:14.10%
controls:2.40%
11
30
304
3120
20
14
296
3146
—
11
0
305
3160
—
20
16
268
3088
33
66
201
2688
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.3e+00
2.7e+00
—
1.0e+50
—
2.7e+00
1.9e+00
cases:3.49%
controls:0.95%
cases:6.33%
controls:0.44%
—
—
cases:3.48%
controls:0.00%
—
—
cases:6.94%
controls:0.52%
cases:14.10%
controls:2.40%
11
30
304
3120
20
14
296
3146
—
11
0
305
3160
—
20
16
268
3088
33
66
201
2688
nifedipine; oral, parenteral
C08CA05 [21601751]
2.8e+00
2.8e+00
—
—
—
—
3.0e+00
cases:5.08%
controls:0.32%
cases:3.48%
controls:0.22%
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.25%
16
10
299
3140
11
7
305
3153
—
—
—
—
11
7
223
2747
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
2.4e+00
3.4e+00
1.0e+50
1.0e+50
—
—
2.7e+00
cases:7.94%
controls:0.76%
cases:9.49%
controls:0.35%
cases:2.85%
controls:0.00%
cases:6.96%
controls:0.00%
—
—
—
—
cases:10.68%
controls:0.76%
25
24
290
3126
30
11
286
3149
9
0
307
3160
22
0
294
3160
—
—
25
21
209
2733
Congestive heart failure
I50.0 [45567179]
3.0e+00
—
—
—
—
3.0e+00
2.6e+00
cases:6.03%
controls:0.32%
—
—
—
—
—
—
—
—
cases:6.60%
controls:0.35%
cases:10.26%
controls:0.87%
19
10
296
3140
—
—
—
—
19
11
269
3093
24
24
210
2730
pH of Arterial blood
2744-1 [3019977]
1.3e+00
2.7e+00
—
1.0e+50
—
2.6e+00
1.9e+00
cases:3.49%
controls:0.95%
cases:6.33%
controls:0.44%
—
—
cases:3.48%
controls:0.00%
—
—
cases:6.60%
controls:0.52%
cases:13.68%
controls:2.32%
11
30
304
3120
20
14
296
3146
—
11
0
305
3160
—
19
16
269
3088
32
64
202
2690
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.3e+00
2.7e+00
—
1.0e+50
—
2.7e+00
1.9e+00
cases:3.49%
controls:0.95%
cases:6.01%
controls:0.44%
—
—
cases:3.48%
controls:0.00%
—
—
cases:6.60%
controls:0.48%
cases:13.68%
controls:2.36%
11
30
304
3120
19
14
297
3146
—
11
0
305
3160
—
19
15
269
3089
32
65
202
2689
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.5e+00
2.2e+00
—
—
—
2.6e+00
2.2e+00
cases:3.17%
controls:0.73%
cases:4.75%
controls:0.54%
—
—
—
—
—
—
cases:6.25%
controls:0.52%
cases:11.11%
controls:1.34%
10
23
305
3127
15
17
301
3143
—
—
—
18
16
270
3088
26
37
208
2717
bisoprolol; oral
C07AB07 [21601689]
1.3e+00
1.6e+00
1.6e+00
—
1.4e+00
1.5e+00
1.1e+00
cases:33.65%
controls:12.32%
cases:35.76%
controls:10.28%
cases:12.34%
controls:2.75%
—
—
cases:11.07%
controls:3.04%
cases:35.07%
controls:10.99%
cases:34.62%
controls:14.42%
106
388
209
2762
113
325
203
2835
39
87
277
3073
—
34
96
273
3058
101
341
187
2763
81
397
153
2357
Gas panel - Arterial blood
24336-0 [3019060]
1.3e+00
3.1e+00
—
1.0e+50
—
2.7e+00
2.6e+00
cases:2.54%
controls:0.70%
cases:4.11%
controls:0.19%
—
—
cases:2.22%
controls:0.00%
—
—
cases:5.21%
controls:0.35%
cases:11.97%
controls:1.02%
8
22
307
3128
13
6
303
3154
—
7
0
309
3160
—
15
11
273
3093
28
28
206
2726
Abdominal ultrasound examination
JN3AE [2001305555]
1.3e+00
2.3e+00
—
—
—
2.9e+00
1.9e+00
cases:3.81%
controls:1.11%
cases:4.11%
controls:0.44%
—
—
—
—
—
—
cases:6.25%
controls:0.35%
cases:8.12%
controls:1.34%
12
35
303
3115
13
14
303
3146
—
—
—
18
11
270
3093
19
37
215
2717
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
5.2e-01
1.2e+00
2.3e+00
1.0e+50
2.4e+00
1.4e+00
1.1e+00
cases:10.48%
controls:6.48%
cases:12.66%
controls:4.37%
cases:5.38%
controls:0.57%
cases:3.16%
controls:0.00%
cases:5.86%
controls:0.57%
cases:13.89%
controls:3.77%
cases:26.07%
controls:10.97%
33
204
282
2946
40
138
276
3022
17
18
299
3142
10
0
306
3160
18
18
289
3136
40
117
248
2987
61
302
173
2452
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
5.1e-01
1.2e+00
2.3e+00
1.0e+50
2.4e+00
1.3e+00
1.0e+00
cases:11.43%
controls:7.17%
cases:14.24%
controls:4.72%
cases:6.01%
controls:0.63%
cases:3.48%
controls:0.00%
cases:6.51%
controls:0.60%
cases:14.24%
controls:4.48%
cases:28.21%
controls:12.38%
36
226
279
2924
45
149
271
3011
19
20
297
3140
11
0
305
3160
20
19
287
3135
41
139
247
2965
66
341
168
2413
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
1.7e+00
2.8e+00
—
1.0e+50
—
—
3.7e+00
cases:2.54%
controls:0.48%
cases:3.16%
controls:0.19%
—
—
cases:2.85%
controls:0.00%
—
—
—
—
cases:6.84%
controls:0.18%
8
15
307
3135
10
6
306
3154
—
9
0
307
3160
—
—
16
5
218
2749
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.5e+00
2.5e+00
—
—
—
2.3e+00
1.9e+00
cases:3.49%
controls:0.83%
cases:4.11%
controls:0.35%
—
—
—
—
—
—
cases:4.51%
controls:0.45%
cases:5.56%
controls:0.87%
11
26
304
3124
13
11
303
3149
—
—
—
13
14
275
3090
13
24
221
2730
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.1e+00
2.1e+00
—
1.0e+50
1.0e+50
2.7e+00
2.3e+00
cases:5.08%
controls:1.78%
cases:5.38%
controls:0.70%
—
—
cases:2.85%
controls:0.00%
cases:1.95%
controls:0.00%
cases:5.90%
controls:0.42%
cases:13.68%
controls:1.56%
16
56
299
3094
17
22
299
3138
—
9
0
307
3160
6
0
301
3154
17
13
271
3091
32
43
202
2711
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
3.0e+00
—
1.0e+50
—
3.1e+00
2.0e+00
—
—
cases:3.16%
controls:0.16%
—
—
cases:1.58%
controls:0.00%
—
—
cases:4.17%
controls:0.19%
cases:8.12%
controls:1.16%
—
10
5
306
3155
—
5
0
311
3160
—
12
6
276
3098
19
32
215
2722
Emergency Room and Inpatient Visit
ERIP [262]
8.8e-01
1.3e+00
2.4e+00
—
2.2e+00
1.3e+00
7.7e-01
cases:6.03%
controls:2.60%
cases:6.96%
controls:1.93%
cases:2.85%
controls:0.25%
—
—
cases:2.93%
controls:0.32%
cases:7.29%
controls:2.13%
cases:15.38%
controls:7.73%
19
82
296
3068
22
61
294
3099
9
8
307
3152
—
9
10
298
3144
21
66
267
3038
36
213
198
2541
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.5e+00
2.8e+00
—
—
—
2.2e+00
1.5e+00
cases:6.03%
controls:1.46%
cases:6.65%
controls:0.41%
—
—
—
—
—
—
cases:4.86%
controls:0.55%
cases:8.12%
controls:1.85%
19
46
296
3104
21
13
295
3147
—
—
—
14
17
274
3087
19
51
215
2703
pH of Venous blood
2746-6 [3012544]
1.0e+00
2.2e+00
—
1.0e+50
2.5e+00
2.0e+00
1.4e+00
cases:1.90%
controls:0.70%
cases:5.06%
controls:0.57%
—
—
cases:1.58%
controls:0.00%
cases:1.95%
controls:0.16%
cases:5.21%
controls:0.77%
cases:7.69%
controls:2.11%
6
22
309
3128
16
18
300
3142
—
5
0
311
3160
6
5
301
3149
15
24
273
3080
18
58
216
2696
One hour or less
ZXE00 [2001311394]
7.2e-01
1.3e+00
—
—
2.9e+00
1.7e+00
1.4e+00
cases:11.43%
controls:5.90%
cases:5.06%
controls:1.46%
—
—
—
—
cases:3.26%
controls:0.19%
cases:6.25%
controls:1.16%
cases:14.53%
controls:4.10%
36
186
279
2964
16
46
300
3114
—
—
10
6
297
3148
18
36
270
3068
34
113
200
2641
Leukocytes [#/volume] in Urine
30405-5 [3018095]
4.5e-01
1.3e+00
1.8e+00
—
2.4e+00
1.6e+00
8.6e-01
cases:6.98%
controls:4.57%
cases:9.18%
controls:2.75%
cases:2.85%
controls:0.47%
—
—
cases:3.91%
controls:0.38%
cases:12.15%
controls:2.80%
cases:19.66%
controls:9.40%
22
144
293
3006
29
87
287
3073
9
15
307
3145
—
12
12
295
3142
35
87
253
3017
46
259
188
2495
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
1.9e+00
—
—
—
—
3.4e+00
2.5e+00
cases:2.54%
controls:0.38%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.19%
cases:5.13%
controls:0.44%
8
12
307
3138
—
—
—
—
16
6
272
3098
12
12
222
2742
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
2.0e+00
—
—
—
—
3.4e+00
2.4e+00
cases:2.54%
controls:0.35%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.19%
cases:4.70%
controls:0.44%
8
11
307
3139
—
—
—
—
16
6
272
3098
11
12
223
2742
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
7.2e-02
4.5e-01
1.7e+00
3.9e+00
1.6e+00
5.6e-01
1.7e-01
cases:22.86%
controls:21.62%
cases:24.37%
controls:17.09%
cases:17.41%
controls:3.77%
cases:10.13%
controls:0.22%
cases:16.61%
controls:3.74%
cases:28.13%
controls:18.23%
cases:41.03%
controls:36.96%
72
681
243
2469
77
540
239
2620
55
119
261
3041
32
7
284
3153
51
118
256
3036
81
566
207
2538
96
1018
138
1736
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
1.6e+00
3.0e+00
—
1.0e+50
—
—
3.2e+00
cases:2.54%
controls:0.51%
cases:4.11%
controls:0.22%
—
—
cases:1.58%
controls:0.00%
—
—
—
—
cases:8.12%
controls:0.36%
8
16
307
3134
13
7
303
3153
—
5
0
311
3160
—
—
19
10
215
2744
Pharmacy visit
OMOP4822462 [581458]
3.0e-01
1.1e+00
1.4e+00
1.4e+00
2.1e+00
1.7e+00
1.1e+00
cases:92.70%
controls:90.35%
cases:92.72%
controls:80.92%
cases:74.37%
controls:41.84%
cases:7.28%
controls:1.93%
cases:85.02%
controls:40.65%
cases:96.18%
controls:81.73%
cases:97.44%
controls:92.96%
292
2846
23
304
293
2557
23
603
235
1322
81
1838
23
61
293
3099
261
1282
46
1872
277
2537
11
567
228
2560
6
194
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.6e-01
1.1e+00
2.2e+00
—
2.0e+00
1.5e+00
7.9e-01
cases:14.29%
controls:8.67%
cases:12.66%
controls:4.62%
cases:5.70%
controls:0.63%
—
—
cases:5.86%
controls:0.86%
cases:15.28%
controls:3.93%
cases:26.50%
controls:14.09%
45
273
270
2877
40
146
276
3014
18
20
298
3140
—
18
27
289
3127
44
122
244
2982
62
388
172
2366
Gout, unspecified
M10.9 [45543454]
2.5e+00
—
—
—
—
3.0e+00
2.0e+00
cases:2.54%
controls:0.22%
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.16%
cases:2.99%
controls:0.40%
8
7
307
3143
—
—
—
—
9
5
279
3099
7
11
227
2743
Nephrology
39 [38004479]
2.4e+00
2.1e+00
—
—
—
2.5e+00
2.5e+00
cases:2.86%
controls:0.25%
cases:1.58%
controls:0.19%
—
—
—
—
—
—
cases:3.47%
controls:0.29%
cases:3.85%
controls:0.33%
9
8
306
3142
5
6
311
3154
—
—
—
10
9
278
3095
9
9
225
2745
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.4e+00
2.0e+00
—
—
—
2.0e+00
2.0e+00
cases:4.44%
controls:1.08%
cases:3.48%
controls:0.47%
—
—
—
—
—
—
cases:2.78%
controls:0.39%
cases:7.26%
controls:1.09%
14
34
301
3116
11
15
305
3145
—
—
—
8
12
280
3092
17
30
217
2724
Erysipelas
A46 [45561706]
1.8e+00
2.2e+00
—
1.0e+50
—
2.0e+00
1.4e+00
cases:6.98%
controls:1.17%
cases:2.53%
controls:0.28%
—
—
cases:1.58%
controls:0.00%
—
—
cases:2.78%
controls:0.39%
cases:5.98%
controls:1.60%
22
37
293
3113
8
9
308
3151
—
5
0
311
3160
—
8
12
280
3092
14
44
220
2710
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.1e+00
1.6e+00
—
—
2.5e+00
1.8e+00
1.5e+00
cases:3.49%
controls:1.17%
cases:4.75%
controls:0.95%
—
—
—
—
cases:1.95%
controls:0.16%
cases:4.17%
controls:0.74%
cases:14.10%
controls:3.63%
11
37
304
3113
15
30
301
3130
—
—
6
5
301
3149
12
23
276
3081
33
100
201
2654
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.0e+00
2.5e+00
—
—
—
2.8e+00
2.1e+00
cases:2.22%
controls:0.79%
cases:3.80%
controls:0.32%
—
—
—
—
—
—
cases:4.17%
controls:0.26%
cases:5.13%
controls:0.69%
7
25
308
3125
12
10
304
3150
—
—
—
12
8
276
3096
12
19
222
2735
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.3e+00
2.9e+00
—
1.0e+50
—
2.6e+00
1.8e+00
cases:2.54%
controls:0.70%
cases:5.06%
controls:0.28%
—
—
cases:2.85%
controls:0.00%
—
—
cases:5.56%
controls:0.42%
cases:10.68%
controls:1.92%
8
22
307
3128
16
9
300
3151
—
9
0
307
3160
—
16
13
272
3091
25
53
209
2701
General Practice
1 [38004446]
6.3e-01
1.2e+00
1.6e+00
—
1.9e+00
1.2e+00
8.3e-01
cases:21.27%
controls:12.54%
cases:13.29%
controls:4.49%
cases:4.11%
controls:0.85%
—
—
cases:4.56%
controls:0.70%
cases:14.93%
controls:5.25%
cases:29.49%
controls:15.36%
67
395
248
2755
42
142
274
3018
13
27
303
3133
—
14
22
293
3132
43
163
245
2941
69
423
165
2331
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.3e+00
2.2e+00
—
—
—
2.0e+00
1.7e+00
cases:4.13%
controls:1.11%
cases:5.38%
controls:0.60%
—
—
—
—
—
—
cases:4.86%
controls:0.71%
cases:10.26%
controls:2.07%
13
35
302
3115
17
19
299
3141
—
—
—
14
22
274
3082
24
57
210
2697
Laboratory Visit
OMOP4822461 [32036]
9.7e-02
3.2e-01
1.5e+00
3.7e+00
1.5e+00
5.1e-01
2.1e-01
cases:35.24%
controls:33.05%
cases:38.29%
controls:30.98%
cases:33.23%
controls:9.97%
cases:22.15%
controls:0.73%
cases:31.60%
controls:9.42%
cases:45.14%
controls:33.09%
cases:58.97%
controls:53.70%
111
1041
204
2109
121
979
195
2181
105
315
211
2845
70
23
246
3137
97
297
210
2857
130
1027
158
2077
138
1479
96
1275
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
1.4e+00
2.2e+00
—
—
—
2.0e+00
1.5e+00
cases:5.40%
controls:1.43%
cases:4.43%
controls:0.51%
—
—
—
—
—
—
cases:2.78%
controls:0.39%
cases:8.55%
controls:2.00%
17
45
298
3105
14
16
302
3144
—
—
—
8
12
280
3092
20
55
214
2699
metoprolol; oral, parenteral
C07AB02 [21601684]
1.2e+00
1.5e+00
1.3e+00
—
1.8e+00
1.3e+00
1.4e+00
cases:9.84%
controls:3.27%
cases:9.81%
controls:2.47%
cases:3.48%
controls:1.01%
—
—
cases:4.23%
controls:0.76%
cases:9.03%
controls:2.51%
cases:10.26%
controls:2.87%
31
103
284
3047
31
78
285
3082
11
32
305
3128
—
13
24
294
3130
26
78
262
3026
24
79
210
2675
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
2.5e+00
2.1e+00
—
—
—
2.4e+00
2.1e+00
cases:3.49%
controls:0.29%
cases:1.58%
controls:0.19%
—
—
—
—
—
—
cases:2.43%
controls:0.23%
cases:6.84%
controls:0.87%
11
9
304
3141
5
6
311
3154
—
—
—
7
7
281
3097
16
24
218
2730
Atrial fibrillation/flutter
K78 [2002000605]
1.4e+00
1.7e+00
—
—
—
2.1e+00
1.9e+00
cases:3.49%
controls:0.89%
cases:3.16%
controls:0.60%
—
—
—
—
—
—
cases:4.17%
controls:0.55%
cases:9.83%
controls:1.60%
11
28
304
3122
10
19
306
3141
—
—
—
12
17
276
3087
23
44
211
2710
Inpatient Visit
IP [9201]
5.9e-01
1.4e+00
1.8e+00
1.0e+50
2.7e+00
1.7e+00
1.2e+00
cases:7.94%
controls:4.54%
cases:7.91%
controls:1.99%
cases:1.58%
controls:0.25%
cases:7.91%
controls:0.00%
cases:5.21%
controls:0.38%
cases:11.11%
controls:2.26%
cases:19.66%
controls:6.79%
25
143
290
3007
25
63
291
3097
5
8
311
3152
25
0
291
3160
16
12
291
3142
32
70
256
3034
46
187
188
2567
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
—
2.5e+00
—
—
—
2.7e+00
1.8e+00
—
—
cases:2.22%
controls:0.19%
—
—
—
—
—
—
cases:2.43%
controls:0.16%
cases:4.70%
controls:0.84%
—
7
6
309
3154
—
—
—
7
5
281
3099
11
23
223
2731
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.1e+00
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:4.76%
controls:1.65%
cases:5.70%
controls:0.89%
—
—
—
—
—
—
cases:7.29%
controls:0.77%
cases:12.39%
controls:2.72%
15
52
300
3098
18
28
298
3132
—
—
—
21
24
267
3080
29
75
205
2679
pH of Blood
11558-4 [3010421]
2.1e+00
—
—
—
—
2.4e+00
2.4e+00
cases:2.54%
controls:0.32%
—
—
—
—
—
—
—
—
cases:1.74%
controls:0.16%
cases:3.42%
controls:0.33%
8
10
307
3140
—
—
—
—
5
5
283
3099
8
9
226
2745
Other specified special examinations
Z01.8 [45581003]
1.4e+00
1.9e+00
—
—
—
2.3e+00
1.2e+00
cases:8.25%
controls:2.22%
cases:5.38%
controls:0.82%
—
—
—
—
—
—
cases:3.82%
controls:0.39%
cases:8.55%
controls:2.69%
26
70
289
3080
17
26
299
3134
—
—
—
11
12
277
3092
20
74
214
2680
Emergency Medicine
93 [38004510]
4.3e-01
1.2e+00
2.2e+00
—
1.5e+00
1.2e+00
7.4e-01
cases:13.33%
controls:9.08%
cases:15.51%
controls:5.44%
cases:6.01%
controls:0.73%
—
—
cases:3.91%
controls:0.86%
cases:15.63%
controls:5.25%
cases:32.48%
controls:18.63%
42
286
273
2864
49
172
267
2988
19
23
297
3137
—
12
27
295
3127
45
163
243
2941
76
513
158
2241
tinzaparin; parenteral
B01AB10 [21600981]
—
2.2e+00
—
—
—
2.8e+00
1.8e+00
—
—
cases:3.16%
controls:0.35%
—
—
—
—
—
—
cases:4.86%
controls:0.32%
cases:6.41%
controls:1.09%
—
10
11
306
3149
—
—
—
14
10
274
3094
15
30
219
2724
Cathetrisation of vein
TPH04 [2001309597]
1.4e+00
2.3e+00
—
—
—
1.7e+00
1.5e+00
cases:6.98%
controls:1.81%
cases:6.65%
controls:0.73%
—
—
—
—
—
—
cases:4.17%
controls:0.81%
cases:10.26%
controls:2.58%
22
57
293
3093
21
23
295
3137
—
—
—
12
25
276
3079
24
71
210
2683
sitagliptin; oral
A10BH01 [21600784]
1.7e+00
1.5e+00
2.0e+00
—
—
1.6e+00
1.0e+00
cases:4.76%
controls:0.92%
cases:3.48%
controls:0.76%
cases:1.90%
controls:0.25%
—
—
—
—
cases:3.13%
controls:0.68%
cases:4.27%
controls:1.56%
15
29
300
3121
11
24
305
3136
6
8
310
3152
—
—
9
21
279
3083
10
43
224
2711
Body temperature
8310-5 [3020891]
—
2.7e+00
—
—
—
2.0e+00
2.0e+00
—
—
cases:2.85%
controls:0.19%
—
—
—
—
—
—
cases:2.08%
controls:0.29%
cases:7.26%
controls:1.02%
—
9
6
307
3154
—
—
—
6
9
282
3095
17
28
217
2726
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
5.4e-01
1.0e+00
2.4e+00
—
2.3e+00
1.0e+00
5.8e-01
cases:7.30%
controls:4.38%
cases:7.28%
controls:2.75%
cases:2.85%
controls:0.25%
—
—
cases:3.26%
controls:0.35%
cases:7.99%
controls:3.06%
cases:13.25%
controls:7.88%
23
138
292
3012
23
87
293
3073
9
8
307
3152
—
10
11
297
3143
23
95
265
3009
31
217
203
2537
Short blood count panel - Blood
55429-5 [40758558]
5.3e-01
1.0e+00
1.4e+00
—
2.1e+00
1.0e+00
1.2e+00
cases:6.98%
controls:4.22%
cases:6.96%
controls:2.66%
cases:3.16%
controls:0.82%
—
—
cases:5.86%
controls:0.73%
cases:8.33%
controls:3.16%
cases:18.80%
controls:6.57%
22
133
293
3017
22
84
294
3076
10
26
306
3134
—
18
23
289
3131
24
98
264
3006
44
181
190
2573
fenoterol and ipratropium bromide
R03AL01 [43534843]
1.4e+00
2.5e+00
—
—
—
2.3e+00
2.0e+00
cases:2.54%
controls:0.67%
cases:2.22%
controls:0.19%
—
—
—
—
—
—
cases:2.43%
controls:0.26%
cases:2.56%
controls:0.36%
8
21
307
3129
7
6
309
3154
—
—
—
7
8
281
3096
6
10
228
2744
Sampling
SPAT1263 [2001700364]
5.2e-01
9.5e-01
1.7e+00
—
2.2e+00
1.0e+00
8.0e-01
cases:11.43%
controls:7.14%
cases:7.28%
controls:2.94%
cases:2.53%
controls:0.47%
—
—
cases:3.58%
controls:0.41%
cases:7.64%
controls:2.93%
cases:18.80%
controls:9.40%
36
225
279
2925
23
93
293
3067
8
15
308
3145
—
11
13
296
3141
22
91
266
3013
44
259
190
2495
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.2e-01
1.0e+00
2.1e+00
—
2.3e+00
1.1e+00
2.4e-01
cases:11.43%
controls:7.14%
cases:11.08%
controls:4.37%
cases:4.11%
controls:0.51%
—
—
cases:4.89%
controls:0.51%
cases:14.24%
controls:5.12%
cases:17.52%
controls:14.34%
36
225
279
2925
35
138
281
3022
13
16
303
3144
—
15
16
292
3138
41
159
247
2945
41
395
193
2359
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
4.7e-01
9.9e-01
2.2e+00
—
2.2e+00
1.1e+00
2.8e-01
cases:10.16%
controls:6.60%
cases:10.76%
controls:4.30%
cases:3.48%
controls:0.38%
—
—
cases:4.56%
controls:0.51%
cases:13.54%
controls:5.06%
cases:17.52%
controls:13.83%
32
208
283
2942
34
136
282
3024
11
12
305
3148
—
14
16
293
3138
39
157
249
2947
41
381
193
2373
Intravenous
ZX120 [2001311495]
9.9e-01
1.8e+00
—
—
—
2.0e+00
2.7e+00
cases:3.17%
controls:1.21%
cases:3.16%
controls:0.54%
—
—
—
—
—
—
cases:3.82%
controls:0.52%
cases:10.26%
controls:0.76%
10
38
305
3112
10
17
306
3143
—
—
—
11
16
277
3088
24
21
210
2733
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.8e-01
1.3e+00
1.3e+00
—
1.3e+00
1.3e+00
6.5e-01
cases:25.08%
controls:14.54%
cases:23.73%
controls:8.04%
cases:5.38%
controls:1.55%
—
—
cases:6.19%
controls:1.78%
cases:25.69%
controls:8.38%
cases:31.20%
controls:19.10%
79
458
236
2692
75
254
241
2906
17
49
299
3111
—
19
56
288
3098
74
260
214
2844
73
526
161
2228
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
4.7e-01
9.6e-01
2.3e+00
—
2.1e+00
1.1e+00
3.6e-01
cases:9.52%
controls:6.16%
cases:8.54%
controls:3.45%
cases:2.85%
controls:0.28%
—
—
cases:2.93%
controls:0.38%
cases:10.76%
controls:3.77%
cases:14.96%
controls:10.97%
30
194
285
2956
27
109
289
3051
9
9
307
3151
—
9
12
298
3142
31
117
257
2987
35
302
199
2452
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.2e+00
2.5e+00
—
1.0e+50
—
2.3e+00
1.6e+00
cases:1.90%
controls:0.60%
cases:4.11%
controls:0.35%
—
—
cases:2.53%
controls:0.00%
—
—
cases:3.82%
controls:0.39%
cases:8.12%
controls:1.67%
6
19
309
3131
13
11
303
3149
—
8
0
308
3160
—
11
12
277
3092
19
46
215
2708
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
1.4e+00
2.7e+00
—
—
—
2.4e+00
1.0e+00
cases:3.81%
controls:0.95%
cases:2.22%
controls:0.16%
—
—
—
—
—
—
cases:2.08%
controls:0.19%
cases:2.14%
controls:0.80%
12
30
303
3120
7
5
309
3155
—
—
—
6
6
282
3098
5
22
229
2732
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1.6e+00
2.6e+00
—
1.0e+50
—
2.1e+00
1.7e+00
cases:2.54%
controls:0.54%
cases:3.16%
controls:0.25%
—
—
cases:1.90%
controls:0.00%
—
—
cases:2.43%
controls:0.29%
cases:6.41%
controls:1.20%
8
17
307
3133
10
8
306
3152
—
6
0
310
3160
—
7
9
281
3095
15
33
219
2721
Sleep apnoea
G47.3 [45562094]
1.0e+00
1.5e+00
1.5e+00
1.0e+50
—
2.3e+00
1.7e+00
cases:6.03%
controls:2.29%
cases:6.01%
controls:1.46%
cases:1.90%
controls:0.41%
cases:2.85%
controls:0.00%
—
—
cases:12.15%
controls:1.42%
cases:15.38%
controls:3.30%
19
72
296
3078
19
46
297
3114
6
13
310
3147
9
0
307
3160
—
35
44
253
3060
36
91
198
2663
Chronic ulcer skin
S97 [2002001061]
2.0e+00
2.5e+00
1.0e+50
—
—
—
1.9e+00
cases:2.86%
controls:0.38%
cases:1.90%
controls:0.16%
cases:1.58%
controls:0.00%
—
—
—
—
—
—
cases:3.42%
controls:0.54%
9
12
306
3138
6
5
310
3155
5
0
311
3160
—
—
—
8
15
226
2739
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.3e+00
2.3e+00
—
—
1.0e+50
2.8e+00
8.8e-01
cases:4.13%
controls:1.17%
cases:4.43%
controls:0.44%
—
—
—
—
cases:2.93%
controls:0.00%
cases:4.86%
controls:0.32%
cases:3.42%
controls:1.45%
13
37
302
3113
14
14
302
3146
—
—
9
0
298
3154
14
10
274
3094
8
40
226
2714
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.4e+00
2.0e+00
—
—
—
2.3e+00
2.0e+00
cases:1.59%
controls:0.41%
cases:3.80%
controls:0.51%
—
—
—
—
—
—
cases:4.51%
controls:0.45%
cases:7.26%
controls:1.05%
5
13
310
3137
12
16
304
3144
—
—
—
13
14
275
3090
17
29
217
2725
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
8.3e-01
2.0e+00
—
—
—
2.6e+00
1.7e+00
cases:2.86%
controls:1.27%
cases:2.85%
controls:0.38%
—
—
—
—
—
—
cases:3.47%
controls:0.26%
cases:7.26%
controls:1.45%
9
40
306
3110
9
12
307
3148
—
—
—
10
8
278
3096
17
40
217
2714
Chronic respiratory failure
J96.1 [45557632]
2.1e+00
2.6e+00
—
—
—
3.7e+00
—
cases:1.59%
controls:0.19%
cases:2.53%
controls:0.19%
—
—
—
—
—
—
cases:6.25%
controls:0.16%
—
—
5
6
310
3144
8
6
308
3154
—
—
—
18
5
270
3099
—
Obesity due to excess calories
E66.01 [2000501501]
1.9e+00
—
—
—
—
2.7e+00
1.7e+00
cases:3.17%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.23%
cases:3.42%
controls:0.62%
10
15
305
3135
—
—
—
—
9
7
279
3097
8
17
226
2737
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
2.8e-01
1.5e+00
—
1.0e+50
—
3.0e+00
1.8e+00
cases:2.22%
controls:1.68%
cases:4.75%
controls:1.08%
—
—
cases:2.53%
controls:0.00%
—
—
cases:7.99%
controls:0.45%
cases:11.54%
controls:2.07%
7
53
308
3097
15
34
301
3126
—
8
0
308
3160
—
23
14
265
3090
27
57
207
2697
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
8.0e-01
1.4e+00
—
—
2.7e+00
1.4e+00
5.3e-01
cases:7.94%
controls:3.75%
cases:6.65%
controls:1.77%
—
—
—
—
cases:2.28%
controls:0.16%
cases:7.99%
controls:2.06%
cases:10.68%
controls:6.57%
25
118
290
3032
21
56
295
3104
—
—
7
5
300
3149
23
64
265
3040
25
181
209
2573
Fever, unspecified
R50.9 [45582716]
3.9e-01
2.0e+00
—
—
—
2.5e+00
1.7e+00
cases:1.90%
controls:1.30%
cases:3.48%
controls:0.47%
—
—
—
—
—
—
cases:3.82%
controls:0.32%
cases:8.12%
controls:1.53%
6
41
309
3109
11
15
305
3145
—
—
—
11
10
277
3094
19
42
215
2712
metformin; oral
A10BA02 [21600747]
1.4e+00
1.4e+00
1.4e+00
—
1.1e+00
1.1e+00
9.7e-01
cases:16.51%
controls:4.86%
cases:14.56%
controls:4.02%
cases:5.38%
controls:1.39%
—
—
cases:3.26%
controls:1.11%
cases:12.15%
controls:4.25%
cases:13.68%
controls:5.66%
52
153
263
2997
46
127
270
3033
17
44
299
3116
—
10
35
297
3119
35
132
253
2972
32
156
202
2598
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.8e-01
7.7e-01
2.1e+00
—
1.6e+00
1.1e+00
7.3e-01
cases:17.14%
controls:12.41%
cases:14.56%
controls:7.28%
cases:6.01%
controls:0.79%
—
—
cases:4.89%
controls:1.05%
cases:17.71%
controls:6.89%
cases:32.48%
controls:18.81%
54
391
261
2759
46
230
270
2930
19
25
297
3135
—
15
33
292
3121
51
214
237
2890
76
518
158
2236
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.7e-01
9.4e-01
2.0e+00
—
2.2e+00
1.1e+00
2.4e-01
cases:10.79%
controls:7.02%
cases:10.44%
controls:4.37%
cases:3.48%
controls:0.47%
—
—
cases:4.56%
controls:0.54%
cases:13.54%
controls:5.12%
cases:17.52%
controls:14.27%
34
221
281
2929
33
138
283
3022
11
15
305
3145
—
14
17
293
3137
39
159
249
2945
41
393
193
2361
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.2e-01
9.9e-01
1.7e+00
—
1.9e+00
8.6e-01
6.7e-01
cases:12.06%
controls:9.90%
cases:12.34%
controls:4.97%
cases:3.16%
controls:0.60%
—
—
cases:4.89%
controls:0.73%
cases:10.76%
controls:4.86%
cases:25.64%
controls:15.00%
38
312
277
2838
39
157
277
3003
10
19
306
3141
—
15
23
292
3131
31
151
257
2953
60
413
174
2341
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.2e+00
2.0e+00
—
—
—
1.8e+00
1.2e+00
cases:6.03%
controls:1.94%
cases:2.85%
controls:0.41%
—
—
—
—
—
—
cases:3.47%
controls:0.61%
cases:5.98%
controls:1.82%
19
61
296
3089
9
13
307
3147
—
—
—
10
19
278
3085
14
50
220
2704
hydroxychloroquine; oral
P01BA02 [21604889]
1.6e+00
1.2e+00
—
—
—
1.7e+00
1.6e+00
cases:6.35%
controls:1.33%
cases:4.11%
controls:1.23%
—
—
—
—
—
—
cases:6.25%
controls:1.22%
cases:6.41%
controls:1.42%
20
42
295
3108
13
39
303
3121
—
—
—
18
38
270
3066
15
39
219
2715
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
1.3e+00
2.6e+00
—
—
—
2.1e+00
1.4e+00
cases:2.22%
controls:0.63%
cases:3.16%
controls:0.25%
—
—
—
—
—
—
cases:3.13%
controls:0.39%
cases:6.41%
controls:1.63%
7
20
308
3130
10
8
306
3152
—
—
—
9
12
279
3092
15
45
219
2709
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
1.6e+00
2.0e+00
—
1.0e+50
—
2.4e+00
—
cases:4.44%
controls:0.92%
cases:1.90%
controls:0.25%
—
—
cases:1.58%
controls:0.00%
—
—
cases:3.47%
controls:0.32%
—
—
14
29
301
3121
6
8
310
3152
—
5
0
311
3160
—
10
10
278
3094
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
3.9e-01
1.3e+00
2.0e+00
—
2.7e+00
9.8e-01
6.8e-01
cases:6.03%
controls:4.16%
cases:5.38%
controls:1.52%
cases:1.90%
controls:0.25%
—
—
cases:2.28%
controls:0.16%
cases:5.21%
controls:2.03%
cases:11.11%
controls:5.95%
19
131
296
3019
17
48
299
3112
6
8
310
3152
—
7
5
300
3149
15
63
273
3041
26
164
208
2590
Nonallergic asthma
J45.1 [45557625]
1.5e+00
2.3e+00
—
—
—
2.1e+00
9.1e-01
cases:3.81%
controls:0.86%
cases:3.48%
controls:0.35%
—
—
—
—
—
—
cases:2.08%
controls:0.26%
cases:2.14%
controls:0.87%
12
27
303
3123
11
11
305
3149
—
—
—
6
8
282
3096
5
24
229
2730
salbutamol; inhalant
R03AC02 [21603256]
1.1e+00
1.4e+00
1.6e+00
—
1.2e+00
9.9e-01
7.1e-01
cases:28.89%
controls:11.56%
cases:21.20%
controls:6.04%
cases:6.33%
controls:1.36%
—
—
cases:2.61%
controls:0.76%
cases:15.97%
controls:6.60%
cases:24.79%
controls:13.98%
91
364
224
2786
67
191
249
2969
20
43
296
3117
—
8
24
299
3130
46
205
242
2899
58
385
176
2369
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
4.8e-01
9.7e-01
1.6e+00
—
1.9e+00
1.4e+00
4.3e-01
cases:8.89%
controls:5.68%
cases:8.23%
controls:3.29%
cases:2.53%
controls:0.51%
—
—
cases:3.58%
controls:0.57%
cases:9.38%
controls:2.58%
cases:12.39%
controls:8.46%
28
179
287
2971
26
104
290
3056
8
16
308
3144
—
11
18
296
3136
27
80
261
3024
29
233
205
2521
insulin detemir; parenteral
A10AE05 [21600740]
1.4e+00
1.5e+00
—
—
—
1.5e+00
1.4e+00
cases:4.44%
controls:1.17%
cases:4.11%
controls:0.92%
—
—
—
—
—
—
cases:4.17%
controls:0.97%
cases:6.41%
controls:1.60%
14
37
301
3113
13
29
303
3131
—
—
—
12
30
276
3074
15
44
219
2710
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
2.3e-01
7.1e-01
1.9e+00
—
1.5e+00
1.1e+00
6.0e-01
cases:14.29%
controls:11.71%
cases:13.92%
controls:7.34%
cases:5.70%
controls:0.89%
—
—
cases:4.56%
controls:1.08%
cases:17.36%
controls:6.54%
cases:29.91%
controls:18.95%
45
369
270
2781
44
232
272
2928
18
28
298
3132
—
14
34
293
3120
50
203
238
2901
70
522
164
2232
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.1e+00
2.0e+00
1.0e+50
—
1.0e+50
2.5e+00
3.4e-01
cases:4.44%
controls:1.52%
cases:5.38%
controls:0.73%
cases:1.90%
controls:0.00%
—
—
cases:2.93%
controls:0.00%
cases:5.56%
controls:0.48%
cases:3.42%
controls:2.47%
14
48
301
3102
17
23
299
3137
6
0
310
3160
—
9
0
298
3154
16
15
272
3089
8
68
226
2686
Osmolality of Urine
2695-5 [3026782]
4.7e-01
1.7e+00
—
—
—
2.4e+00
1.6e+00
cases:5.40%
controls:3.43%
cases:6.96%
controls:1.36%
—
—
—
—
—
—
cases:8.33%
controls:0.84%
cases:15.81%
controls:3.78%
17
108
298
3042
22
43
294
3117
—
—
—
24
26
264
3078
37
104
197
2650
Supine thorax X-ray examination
GD1QA [2001303648]
1.3e+00
1.5e+00
—
1.0e+50
—
1.4e+00
1.3e+00
cases:5.40%
controls:1.46%
cases:3.48%
controls:0.82%
—
—
cases:2.22%
controls:0.00%
—
—
cases:3.82%
controls:0.97%
cases:9.83%
controls:2.76%
17
46
298
3104
11
26
305
3134
—
7
0
309
3160
—
11
30
277
3074
23
76
211
2678
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
1.9e+00
3.0e+00
1.0e+50
—
1.0e+50
—
2.5e+00
cases:1.90%
controls:0.29%
cases:3.80%
controls:0.19%
cases:1.58%
controls:0.00%
—
—
cases:1.95%
controls:0.00%
—
—
cases:6.84%
controls:0.58%
6
9
309
3141
12
6
304
3154
5
0
311
3160
—
6
0
301
3154
—
16
16
218
2738
Cardiodefibrillation
TFP20 [2001303224]
1.4e+00
2.0e+00
—
—
—
—
2.1e+00
cases:3.81%
controls:0.95%
cases:2.53%
controls:0.35%
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.47%
12
30
303
3120
8
11
308
3149
—
—
—
—
9
13
225
2741
isosorbide mononitrate; oral
C01DA14 [21600324]
1.2e+00
1.7e+00
1.1e+00
—
1.6e+00
1.1e+00
5.9e-01
cases:8.25%
controls:2.70%
cases:10.13%
controls:2.09%
cases:1.90%
controls:0.63%
—
—
cases:2.93%
controls:0.60%
cases:6.60%
controls:2.29%
cases:5.56%
controls:3.16%
26
85
289
3065
32
66
284
3094
6
20
310
3140
—
9
19
298
3135
19
71
269
3033
13
87
221
2667
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
2.3e+00
—
—
—
2.0e+00
1.2e+00
—
—
cases:3.48%
controls:0.35%
—
—
—
—
—
—
cases:2.08%
controls:0.29%
cases:5.13%
controls:1.56%
—
11
11
305
3149
—
—
—
6
9
282
3095
12
43
222
2711
Shortness of breath/dyspnoea
R02 [2002000883]
1.8e+00
2.3e+00
—
—
—
1.5e+00
1.4e+00
cases:6.03%
controls:1.08%
cases:3.48%
controls:0.35%
—
—
—
—
—
—
cases:1.74%
controls:0.39%
cases:5.98%
controls:1.49%
19
34
296
3116
11
11
305
3149
—
—
—
5
12
283
3092
14
41
220
2713
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
9.3e-01
3.2e+00
—
—
—
2.3e+00
—
cases:1.90%
controls:0.76%
cases:3.80%
controls:0.16%
—
—
—
—
—
—
cases:3.47%
controls:0.35%
—
—
6
24
309
3126
12
5
304
3155
—
—
—
10
11
278
3093
—
Base excess in Venous blood by calculation
1927-3 [3002032]
8.8e-01
2.2e+00
—
1.0e+50
—
1.8e+00
1.5e+00
cases:1.59%
controls:0.67%
cases:4.75%
controls:0.54%
—
—
cases:1.58%
controls:0.00%
—
—
cases:4.17%
controls:0.71%
cases:8.12%
controls:2.00%
5
21
310
3129
15
17
301
3143
—
5
0
311
3160
—
12
22
276
3082
19
55
215
2699
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.0e+00
2.0e+00
—
—
—
1.9e+00
1.6e+00
cases:2.86%
controls:1.05%
cases:4.11%
controls:0.57%
—
—
—
—
—
—
cases:4.17%
controls:0.64%
cases:9.83%
controls:2.25%
9
33
306
3117
13
18
303
3142
—
—
—
12
20
276
3084
23
62
211
2692
Gas panel - Venous blood
24339-4 [3000991]
1.0e+00
2.2e+00
—
—
—
2.0e+00
1.2e+00
cases:1.59%
controls:0.57%
cases:4.11%
controls:0.47%
—
—
—
—
—
—
cases:3.82%
controls:0.52%
cases:5.98%
controls:1.82%
5
18
310
3132
13
15
303
3145
—
—
—
11
16
277
3088
14
50
220
2704
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.5e+00
2.2e+00
—
—
—
1.6e+00
1.7e+00
cases:1.90%
controls:0.44%
cases:4.75%
controls:0.54%
—
—
—
—
—
—
cases:3.13%
controls:0.68%
cases:6.84%
controls:1.34%
6
14
309
3136
15
17
301
3143
—
—
—
9
21
279
3083
16
37
218
2717
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
—
2.0e+00
—
—
—
1.8e+00
1.7e+00
—
—
cases:2.85%
controls:0.41%
—
—
—
—
—
—
cases:2.43%
controls:0.42%
cases:5.98%
controls:1.13%
—
9
13
307
3147
—
—
—
7
13
281
3091
14
31
220
2723
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.3e+00
2.3e+00
—
—
—
1.6e+00
1.6e+00
cases:1.90%
controls:0.51%
cases:5.06%
controls:0.54%
—
—
—
—
—
—
cases:3.47%
controls:0.74%
cases:6.41%
controls:1.38%
6
16
309
3134
16
17
300
3143
—
—
—
10
23
278
3081
15
38
219
2716
Diabetes non-insulin dependent
T90 [2002001131]
1.3e+00
1.2e+00
—
—
—
1.5e+00
1.4e+00
cases:9.21%
controls:2.76%
cases:6.01%
controls:1.80%
—
—
—
—
—
—
cases:8.33%
controls:1.90%
cases:14.53%
controls:4.10%
29
87
286
3063
19
57
297
3103
—
—
—
24
59
264
3045
34
113
200
2641
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
4.2e-01
1.7e+00
—
—
—
2.4e+00
1.4e+00
cases:1.59%
controls:1.05%
cases:2.53%
controls:0.47%
—
—
—
—
—
—
cases:4.86%
controls:0.48%
cases:4.27%
controls:1.09%
5
33
310
3117
8
15
308
3145
—
—
—
14
15
274
3089
10
30
224
2724
Heart failure
I50 [45581779]
2.5e+00
2.9e+00
1.0e+50
—
—
—
1.3e+00
cases:3.81%
controls:0.32%
cases:2.85%
controls:0.16%
cases:1.58%
controls:0.00%
—
—
—
—
—
—
cases:2.56%
controls:0.73%
12
10
303
3140
9
5
307
3155
5
0
311
3160
—
—
—
6
20
228
2734
Monitored bed care
WX892 [2001310850]
1.5e+00
2.3e+00
—
—
—
—
1.6e+00
cases:2.86%
controls:0.67%
cases:2.22%
controls:0.22%
—
—
—
—
—
—
—
—
cases:3.42%
controls:0.69%
9
21
306
3129
7
7
309
3153
—
—
—
—
8
19
226
2735
Respiratory and circulatory monitoring
WX700 [2001310817]
1.3e+00
1.1e+00
—
1.0e+50
—
2.3e+00
1.8e+00
cases:5.40%
controls:1.49%
cases:2.53%
controls:0.85%
—
—
cases:1.58%
controls:0.00%
—
—
cases:4.17%
controls:0.45%
cases:12.82%
controls:2.29%
17
47
298
3103
8
27
308
3133
—
5
0
311
3160
—
12
14
276
3090
30
63
204
2691
Diffusion capacity of lung
54715006 [4182985]
2.2e+00
—
1.0e+50
—
—
—
3.2e+00
cases:2.86%
controls:0.32%
—
—
cases:1.58%
controls:0.00%
—
—
—
—
—
—
cases:4.27%
controls:0.18%
9
10
306
3140
—
5
0
311
3160
—
—
—
10
5
224
2749
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.4e+00
2.1e+00
—
—
—
1.6e+00
1.7e+00
cases:1.59%
controls:0.41%
cases:4.43%
controls:0.54%
—
—
—
—
—
—
cases:3.13%
controls:0.68%
cases:6.84%
controls:1.31%
5
13
310
3137
14
17
302
3143
—
—
—
9
21
279
3083
16
36
218
2718
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
—
2.5e+00
—
—
1.0e+50
2.9e+00
1.7e+00
—
—
cases:2.22%
controls:0.19%
—
—
—
—
cases:1.63%
controls:0.00%
cases:3.47%
controls:0.19%
cases:2.14%
controls:0.40%
—
7
6
309
3154
—
—
5
0
302
3154
10
6
278
3098
5
11
229
2743
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
—
2.5e+00
—
—
1.0e+50
2.9e+00
1.7e+00
—
—
cases:2.22%
controls:0.19%
—
—
—
—
cases:1.63%
controls:0.00%
cases:3.47%
controls:0.19%
cases:2.14%
controls:0.40%
—
7
6
309
3154
—
—
5
0
302
3154
10
6
278
3098
5
11
229
2743
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
—
2.5e+00
—
—
1.0e+50
2.9e+00
1.7e+00
—
—
cases:2.22%
controls:0.19%
—
—
—
—
cases:1.63%
controls:0.00%
cases:3.47%
controls:0.19%
cases:2.14%
controls:0.40%
—
7
6
309
3154
—
—
5
0
302
3154
10
6
278
3098
5
11
229
2743
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.2e+00
2.1e+00
—
—
—
1.6e+00
1.7e+00
cases:1.59%
controls:0.48%
cases:4.43%
controls:0.54%
—
—
—
—
—
—
cases:3.47%
controls:0.74%
cases:6.41%
controls:1.27%
5
15
310
3135
14
17
302
3143
—
—
—
10
23
278
3081
15
35
219
2719
losartan; oral
C09CA01 [21601824]
1.3e+00
1.4e+00
1.4e+00
—
1.2e+00
1.2e+00
7.8e-01
cases:8.57%
controls:2.44%
cases:8.23%
controls:2.12%
cases:3.16%
controls:0.79%
—
—
cases:1.95%
controls:0.60%
cases:7.99%
controls:2.48%
cases:8.97%
controls:4.32%
27
77
288
3073
26
67
290
3093
10
25
306
3135
—
6
19
301
3135
23
77
265
3027
21
119
213
2635
Intensive care
WX872 [2001310844]
1.9e+00
—
—
1.0e+50
—
—
3.5e+00
cases:2.86%
controls:0.44%
—
—
—
—
cases:2.22%
controls:0.00%
—
—
—
—
cases:5.56%
controls:0.18%
9
14
306
3136
—
—
7
0
309
3160
—
—
13
5
221
2749
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
8.8e-01
2.2e+00
—
1.0e+50
—
1.7e+00
1.4e+00
cases:1.59%
controls:0.67%
cases:4.75%
controls:0.54%
—
—
cases:1.58%
controls:0.00%
—
—
cases:3.82%
controls:0.71%
cases:7.69%
controls:2.00%
5
21
310
3129
15
17
301
3143
—
5
0
311
3160
—
11
22
277
3082
18
55
216
2699
cefalexin; oral
J01DB01 [21602870]
4.7e-01
1.0e+00
1.3e+00
—
2.1e+00
9.4e-01
7.1e-01
cases:36.19%
controls:26.10%
cases:18.04%
controls:7.22%
cases:2.22%
controls:0.60%
—
—
cases:3.58%
controls:0.44%
cases:15.97%
controls:6.89%
cases:38.89%
controls:23.75%
114
822
201
2328
57
228
259
2932
7
19
309
3141
—
11
14
296
3140
46
214
242
2890
91
654
143
2100
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.7e-01
7.2e-01
1.8e+00
—
1.9e+00
8.4e-01
4.4e-01
cases:28.89%
controls:25.52%
cases:32.59%
controls:18.99%
cases:19.30%
controls:3.77%
—
—
cases:18.89%
controls:3.33%
cases:37.15%
controls:20.36%
cases:54.27%
controls:43.21%
91
804
224
2346
103
600
213
2560
61
119
255
3041
—
58
105
249
3049
107
632
181
2472
127
1190
107
1564
Other interstitial pulmonary diseases with fibrosis
J84.1 [45557630]
2.6e+00
2.3e+00
—
—
—
2.7e+00
1.8e+00
cases:2.86%
controls:0.22%
cases:1.58%
controls:0.16%
—
—
—
—
—
—
cases:2.78%
controls:0.19%
cases:2.56%
controls:0.44%
9
7
306
3143
5
5
311
3155
—
—
—
8
6
280
3098
6
12
228
2742
Case Management Agency
251B00000X [38004193]
4.4e-01
4.0e-01
8.8e-01
2.5e+00
8.9e-01
5.3e-01
3.1e-01
cases:65.71%
controls:55.21%
cases:60.44%
controls:50.63%
cases:35.76%
controls:18.73%
cases:17.72%
controls:1.74%
cases:38.11%
controls:20.13%
cases:66.32%
controls:53.77%
cases:82.05%
controls:77.05%
207
1739
108
1411
191
1600
125
1560
113
592
203
2568
56
55
260
3105
117
635
190
2519
191
1669
97
1435
192
2122
42
632
Spirometry
127783003 [4133840]
2.0e+00
1.0e+50
—
—
—
—
3.2e+00
cases:1.90%
controls:0.25%
cases:2.22%
controls:0.00%
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.22%
6
8
309
3142
7
0
309
3160
—
—
—
—
12
6
222
2748
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.1e+00
2.0e+00
—
—
1.0e+50
1.9e+00
1.3e+00
cases:3.81%
controls:1.24%
cases:3.48%
controls:0.51%
—
—
—
—
cases:1.95%
controls:0.00%
cases:3.82%
controls:0.58%
cases:8.12%
controls:2.25%
12
39
303
3111
11
16
305
3144
—
—
6
0
301
3154
11
18
277
3086
19
62
215
2692
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
2.9e+00
—
1.0e+50
—
2.3e+00
7.5e-01
—
—
cases:2.85%
controls:0.16%
—
—
cases:1.90%
controls:0.00%
—
—
cases:3.13%
controls:0.32%
cases:2.14%
controls:1.02%
—
9
5
307
3155
—
6
0
310
3160
—
9
10
279
3094
5
28
229
2726
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
5.5e-01
2.1e+00
—
1.0e+50
—
1.7e+00
1.4e+00
cases:1.90%
controls:1.11%
cases:4.11%
controls:0.51%
—
—
cases:1.90%
controls:0.00%
—
—
cases:3.82%
controls:0.74%
cases:9.40%
controls:2.47%
6
35
309
3115
13
16
303
3144
—
6
0
310
3160
—
11
23
277
3081
22
68
212
2686
Social worker
Z2446 [2001311559]
7.8e-01
2.0e+00
—
—
—
3.0e+00
2.2e+00
cases:1.59%
controls:0.73%
cases:1.58%
controls:0.22%
—
—
—
—
—
—
cases:4.17%
controls:0.23%
cases:4.27%
controls:0.47%
5
23
310
3127
5
7
311
3153
—
—
—
12
7
276
3097
10
13
224
2741
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
2.3e+00
—
1.0e+50
—
1.6e+00
1.3e+00
—
—
cases:4.11%
controls:0.44%
—
—
cases:1.58%
controls:0.00%
—
—
cases:2.78%
controls:0.55%
cases:5.98%
controls:1.74%
—
13
14
303
3146
—
5
0
311
3160
—
8
17
280
3087
14
48
220
2706
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
7.6e-01
1.9e+00
—
—
—
1.8e+00
1.5e+00
cases:2.22%
controls:1.05%
cases:5.38%
controls:0.82%
—
—
—
—
—
—
cases:5.56%
controls:0.97%
cases:10.26%
controls:2.58%
7
33
308
3117
17
26
299
3134
—
—
—
16
30
272
3074
24
71
210
2683
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.4e+00
1.8e+00
1.0e+50
—
—
2.0e+00
1.0e+00
cases:4.76%
controls:1.24%
cases:3.80%
controls:0.63%
cases:1.90%
controls:0.00%
—
—
—
—
cases:4.17%
controls:0.61%
cases:4.27%
controls:1.56%
15
39
300
3111
12
20
304
3140
6
0
310
3160
—
—
12
19
276
3085
10
43
224
2711
Psychiatry
26 [38004469]
3.1e-01
8.6e-01
1.4e+00
—
2.2e+00
1.6e+00
1.4e+00
cases:4.76%
controls:3.52%
cases:5.06%
controls:2.22%
cases:2.53%
controls:0.63%
—
—
cases:4.23%
controls:0.51%
cases:7.99%
controls:1.77%
cases:12.39%
controls:3.34%
15
111
300
3039
16
70
300
3090
8
20
308
3140
—
13
16
294
3138
23
55
265
3049
29
92
205
2662
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.3e+00
1.5e+00
—
—
—
2.0e+00
1.6e+00
cases:3.17%
controls:0.89%
cases:2.85%
controls:0.63%
—
—
—
—
—
—
cases:3.47%
controls:0.48%
cases:11.97%
controls:2.69%
10
28
305
3122
9
20
307
3140
—
—
—
10
15
278
3089
28
74
206
2680
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.2e+00
1.5e+00
—
—
—
1.9e+00
1.6e+00
cases:2.86%
controls:0.89%
cases:2.85%
controls:0.63%
—
—
—
—
—
—
cases:3.47%
controls:0.52%
cases:12.39%
controls:2.72%
9
28
306
3122
9
20
307
3140
—
—
—
10
16
278
3088
29
75
205
2679
Gas panel - Capillary blood
24337-8 [3022313]
—
—
—
—
—
2.8e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:0.23%
cases:5.56%
controls:0.58%
—
—
—
—
—
10
7
278
3097
13
16
221
2738
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.3e+00
2.1e+00
—
—
—
1.3e+00
1.7e+00
cases:3.49%
controls:0.95%
cases:2.22%
controls:0.28%
—
—
—
—
—
—
cases:1.74%
controls:0.48%
cases:7.26%
controls:1.45%
11
30
304
3120
7
9
309
3151
—
—
—
5
15
283
3089
17
40
217
2714
Ambulatory ECG
XF404 [2001303370]
1.3e+00
2.5e+00
—
—
—
—
2.5e+00
cases:2.86%
controls:0.83%
cases:1.90%
controls:0.16%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.47%
9
26
306
3124
6
5
310
3155
—
—
—
—
13
13
221
2741
losartan and diuretics
C09DA01 [21601834]
1.7e+00
1.8e+00
—
—
—
1.5e+00
1.4e+00
cases:3.81%
controls:0.70%
cases:3.80%
controls:0.63%
—
—
—
—
—
—
cases:3.13%
controls:0.74%
cases:3.85%
controls:0.98%
12
22
303
3128
12
20
304
3140
—
—
—
9
23
279
3081
9
27
225
2727
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
—
2.3e+00
—
—
1.0e+50
2.7e+00
1.7e+00
—
—
cases:1.90%
controls:0.19%
—
—
—
—
cases:1.63%
controls:0.00%
cases:2.78%
controls:0.19%
cases:2.14%
controls:0.40%
—
6
6
310
3154
—
—
5
0
302
3154
8
6
280
3098
5
11
229
2743
enalapril; oral, parenteral
C09AA02 [21601786]
2.0e+00
1.7e+00
—
—
1.7e+00
1.4e+00
5.0e-01
cases:9.84%
controls:1.52%
cases:6.01%
controls:1.17%
—
—
—
—
cases:2.28%
controls:0.41%
cases:5.21%
controls:1.39%
cases:3.85%
controls:2.36%
31
48
284
3102
19
37
297
3123
—
—
7
13
300
3141
15
43
273
3061
9
65
225
2689
Mitral (valve) insufficiency
I34.09 [2000502484]
2.3e+00
2.7e+00
—
1.0e+50
—
—
1.1e+00
cases:3.49%
controls:0.35%
cases:3.48%
controls:0.25%
—
—
cases:1.58%
controls:0.00%
—
—
—
—
cases:2.14%
controls:0.73%
11
11
304
3139
11
8
305
3152
—
5
0
311
3160
—
—
5
20
229
2734
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
8.4e-02
6.9e-01
1.6e+00
—
1.9e+00
7.6e-01
4.0e-01
cases:21.27%
controls:19.90%
cases:23.42%
controls:13.32%
cases:7.28%
controls:1.55%
—
—
cases:9.12%
controls:1.46%
cases:24.65%
controls:13.24%
cases:43.16%
controls:33.66%
67
627
248
2523
74
421
242
2739
23
49
293
3111
—
28
46
279
3108
71
411
217
2693
101
927
133
1827
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
1.8e+00
—
—
1.0e+50
—
—
3.2e+00
cases:2.22%
controls:0.38%
—
—
—
—
cases:1.58%
controls:0.00%
—
—
—
—
cases:8.12%
controls:0.36%
7
12
308
3138
—
—
5
0
311
3160
—
—
19
10
215
2744
Scheduled procedure
ZXD10 [2001311387]
7.5e-01
8.9e-01
—
1.0e+50
—
2.5e+00
1.7e+00
cases:12.38%
controls:6.29%
cases:4.43%
controls:1.87%
—
—
cases:3.80%
controls:0.00%
—
—
cases:11.81%
controls:1.06%
cases:15.81%
controls:3.34%
39
198
276
2952
14
59
302
3101
—
12
0
304
3160
—
34
33
254
3071
37
92
197
2662
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
—
—
—
—
—
2.8e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.19%
cases:5.56%
controls:0.69%
—
—
—
—
—
9
6
279
3098
13
19
221
2735
tadalafil; oral
G04BE08 [21602653]
—
—
—
—
—
2.6e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:6.60%
controls:0.52%
cases:8.55%
controls:0.91%
—
—
—
—
—
19
16
269
3088
20
25
214
2729
Home Visit
OMOP4822459 [581476]
5.4e-01
1.1e+00
1.6e+00
—
1.3e+00
9.1e-01
5.2e-01
cases:6.98%
controls:4.19%
cases:8.23%
controls:2.94%
cases:3.80%
controls:0.76%
—
—
cases:3.58%
controls:1.01%
cases:8.68%
controls:3.67%
cases:15.38%
controls:9.77%
22
132
293
3018
26
93
290
3067
12
24
304
3136
—
11
32
296
3122
25
114
263
2990
36
269
198
2485
amiodarone; oral, parenteral
C01BD01 [21600270]
1.6e+00
—
—
—
—
2.6e+00
2.4e+00
cases:1.90%
controls:0.38%
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.19%
cases:2.99%
controls:0.29%
6
12
309
3138
—
—
—
—
7
6
281
3098
7
8
227
2746
salmeterol and fluticasone
R03AK06 [21603280]
1.3e+00
1.2e+00
8.5e-01
—
—
1.3e+00
1.2e+00
cases:8.57%
controls:2.51%
cases:6.33%
controls:2.03%
cases:1.90%
controls:0.82%
—
—
—
—
cases:7.29%
controls:2.16%
cases:9.40%
controls:3.16%
27
79
288
3071
20
64
296
3096
6
26
310
3134
—
—
21
67
267
3037
22
87
212
2667
Epistaxis
R04.0 [45606791]
1.5e+00
—
—
—
—
2.7e+00
2.2e+00
cases:2.54%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.82%
controls:0.26%
cases:5.13%
controls:0.62%
8
19
307
3131
—
—
—
—
11
8
277
3096
12
17
222
2737
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
9.3e-01
1.7e+00
—
—
—
3.0e+00
1.9e+00
cases:1.59%
controls:0.63%
cases:1.58%
controls:0.28%
—
—
—
—
—
—
cases:3.13%
controls:0.16%
cases:2.99%
controls:0.47%
5
20
310
3130
5
9
311
3151
—
—
—
9
5
279
3099
7
13
227
2741
Urgent procedure
ZXD05 [2001311386]
8.9e-01
1.4e+00
—
1.0e+50
—
1.4e+00
1.1e+00
cases:8.57%
controls:3.71%
cases:4.11%
controls:1.04%
—
—
cases:1.58%
controls:0.00%
—
—
cases:3.82%
controls:0.97%
cases:9.40%
controls:3.20%
27
117
288
3033
13
33
303
3127
—
5
0
311
3160
—
11
30
277
3074
22
88
212
2666
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
1.1e+00
1.3e+00
—
—
—
2.9e+00
1.9e+00
cases:1.59%
controls:0.51%
cases:1.58%
controls:0.44%
—
—
—
—
—
—
cases:3.82%
controls:0.23%
cases:6.84%
controls:1.05%
5
16
310
3134
5
14
311
3146
—
—
—
11
7
277
3097
16
29
218
2725
Left ventricular failure
I50.1 [45543181]
1.9e+00
2.9e+00
—
—
—
—
2.1e+00
cases:2.22%
controls:0.35%
cases:2.85%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.25%
7
11
308
3139
9
5
307
3155
—
—
—
—
5
7
229
2747
Thorax CT examination
GD1AD [2001303618]
—
—
—
—
—
2.1e+00
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.08%
controls:0.26%
cases:5.98%
controls:0.44%
—
—
—
—
—
6
8
282
3096
14
12
220
2742
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
9.3e-01
2.2e+00
—
—
—
2.6e+00
—
cases:2.86%
controls:1.14%
cases:1.90%
controls:0.22%
—
—
—
—
—
—
cases:2.08%
controls:0.16%
—
—
9
36
306
3114
6
7
310
3153
—
—
—
6
5
282
3099
—
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
—
2.8e+00
—
—
—
1.9e+00
8.3e-01
—
—
cases:2.53%
controls:0.16%
—
—
—
—
—
—
cases:2.43%
controls:0.35%
cases:2.14%
controls:0.94%
—
8
5
308
3155
—
—
—
7
11
281
3093
5
26
229
2728
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
3.3e-01
1.6e+00
2.0e+00
—
1.8e+00
9.9e-01
6.9e-01
cases:8.89%
controls:6.57%
cases:7.28%
controls:1.49%
cases:1.90%
controls:0.25%
—
—
cases:1.95%
controls:0.32%
cases:5.90%
controls:2.29%
cases:12.82%
controls:6.86%
28
207
287
2943
23
47
293
3113
6
8
310
3152
—
6
10
301
3144
17
71
271
3033
30
189
204
2565
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
9.8e-01
1.1e+00
—
—
—
2.2e+00
1.5e+00
cases:9.21%
controls:3.68%
cases:2.85%
controls:0.98%
—
—
—
—
—
—
cases:9.03%
controls:1.06%
cases:14.10%
controls:3.70%
29
116
286
3034
9
31
307
3129
—
—
—
26
33
262
3071
33
102
201
2652
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
-6.6e-02
6.7e-01
1.6e+00
—
1.7e+00
7.0e-01
3.2e-01
cases:14.29%
controls:15.11%
cases:16.46%
controls:9.18%
cases:4.43%
controls:0.92%
—
—
cases:5.54%
controls:1.11%
cases:17.01%
controls:9.25%
cases:30.77%
controls:24.40%
45
476
270
2674
52
290
264
2870
14
29
302
3131
—
17
35
290
3119
49
287
239
2817
72
672
162
2082
Coronary angiography
AN1 [2000200163]
1.2e+00
3.3e+00
—
1.0e+50
—
—
—
cases:4.76%
controls:1.46%
cases:5.06%
controls:0.19%
—
—
cases:1.58%
controls:0.00%
—
—
—
—
—
—
15
46
300
3104
16
6
300
3154
—
5
0
311
3160
—
—
—
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
1.1e+00
2.5e+00
—
—
—
—
2.0e+00
cases:2.54%
controls:0.89%
cases:1.90%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.40%
8
28
307
3122
6
5
310
3155
—
—
—
—
7
11
227
2743
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
9.2e-01
1.4e+00
1.4e+00
—
1.4e+00
1.2e+00
9.7e-01
cases:12.70%
controls:5.49%
cases:8.86%
controls:2.28%
cases:2.22%
controls:0.54%
—
—
cases:1.95%
controls:0.51%
cases:8.33%
controls:2.67%
cases:15.38%
controls:6.46%
40
173
275
2977
28
72
288
3088
7
17
309
3143
—
6
16
301
3138
24
83
264
3021
36
178
198
2576
apixaban; oral
B01AF02 [43534762]
1.1e+00
1.4e+00
1.3e+00
—
1.5e+00
1.6e+00
9.2e-01
cases:2.86%
controls:0.95%
cases:3.80%
controls:0.98%
cases:1.90%
controls:0.54%
—
—
cases:3.26%
controls:0.73%
cases:5.56%
controls:1.22%
cases:6.41%
controls:2.65%
9
30
306
3120
12
31
304
3129
6
17
310
3143
—
10
23
297
3131
16
38
272
3066
15
73
219
2681
azathioprine; oral, parenteral
L04AX01 [21603927]
2.1e+00
1.9e+00
—
—
—
—
2.4e+00
cases:3.17%
controls:0.41%
cases:1.90%
controls:0.28%
—
—
—
—
—
—
—
—
cases:3.42%
controls:0.33%
10
13
305
3137
6
9
310
3151
—
—
—
—
8
9
226
2745
candesartan and diuretics
C09DA06 [21601838]
2.5e+00
1.9e+00
—
—
—
—
—
cases:4.13%
controls:0.35%
cases:2.53%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
13
11
302
3139
8
12
308
3148
—
—
—
—
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
4.0e-01
9.4e-01
8.5e-01
—
1.6e+00
1.0e+00
9.2e-01
cases:11.43%
controls:7.97%
cases:8.86%
controls:3.67%
cases:1.90%
controls:0.82%
—
—
cases:2.93%
controls:0.63%
cases:10.07%
controls:3.93%
cases:17.52%
controls:7.77%
36
251
279
2899
28
116
288
3044
6
26
310
3134
—
9
20
298
3134
29
122
259
2982
41
214
193
2540
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
2.1e+00
—
—
—
—
—
2.3e+00
cases:2.54%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.22%
8
10
307
3140
—
—
—
—
—
5
6
229
2748
pH of Capillary blood
2745-8 [3009343]
1.1e+00
1.3e+00
—
—
—
2.5e+00
1.9e+00
cases:1.59%
controls:0.54%
cases:1.90%
controls:0.51%
—
—
—
—
—
—
cases:4.17%
controls:0.35%
cases:6.84%
controls:1.09%
5
17
310
3133
6
16
310
3144
—
—
—
12
11
276
3093
16
30
218
2724
Endocrinology
46 [38004485]
9.5e-01
1.0e+00
—
—
—
1.7e+00
1.7e+00
cases:5.40%
controls:2.16%
cases:4.11%
controls:1.49%
—
—
—
—
—
—
cases:7.64%
controls:1.45%
cases:13.25%
controls:2.69%
17
68
298
3082
13
47
303
3113
—
—
—
22
45
266
3059
31
74
203
2680
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
9.7e-01
2.8e+00
—
—
—
1.6e+00
1.5e+00
cases:2.22%
controls:0.86%
cases:3.16%
controls:0.19%
—
—
—
—
—
—
cases:2.43%
controls:0.52%
cases:4.27%
controls:0.94%
7
27
308
3123
10
6
306
3154
—
—
—
7
16
281
3088
10
26
224
2728
Monitoring the use of the aid
R5140 [2001310249]
1.1e+00
1.1e+00
—
—
—
2.3e+00
2.1e+00
cases:2.54%
controls:0.86%
cases:1.58%
controls:0.54%
—
—
—
—
—
—
cases:3.47%
controls:0.35%
cases:8.97%
controls:1.23%
8
27
307
3123
5
17
311
3143
—
—
—
10
11
278
3093
21
34
213
2720
Vascular Surgery
77 [38004496]
1.2e+00
1.4e+00
—
—
2.2e+00
1.8e+00
8.6e-01
cases:7.30%
controls:2.22%
cases:3.48%
controls:0.92%
—
—
—
—
cases:1.63%
controls:0.19%
cases:4.51%
controls:0.81%
cases:5.98%
controls:2.61%
23
70
292
3080
11
29
305
3131
—
—
5
6
302
3148
13
25
275
3079
14
72
220
2682
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
—
—
—
2.6e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.19%
cases:3.42%
controls:0.58%
—
—
—
—
—
7
6
281
3098
8
16
226
2738
Ultrasound examination of lower leg veins
PH2AE [2001309451]
1.8e+00
2.5e+00
—
1.0e+50
—
1.7e+00
1.0e+00
cases:6.98%
controls:1.21%
cases:3.48%
controls:0.28%
—
—
cases:1.58%
controls:0.00%
—
—
cases:2.08%
controls:0.39%
cases:3.85%
controls:1.42%
22
38
293
3112
11
9
305
3151
—
5
0
311
3160
—
6
12
282
3092
9
39
225
2715
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.1e+00
1.3e+00
—
—
—
2.5e+00
1.8e+00
cases:1.59%
controls:0.54%
cases:1.90%
controls:0.51%
—
—
—
—
—
—
cases:4.17%
controls:0.35%
cases:6.84%
controls:1.16%
5
17
310
3133
6
16
310
3144
—
—
—
12
11
276
3093
16
32
218
2722
Atrial fibrillation and atrial flutter, unspecified
I48.9 [45755409]
—
—
—
—
—
2.6e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.08%
controls:0.16%
cases:4.27%
controls:0.80%
—
—
—
—
—
6
5
282
3099
10
22
224
2732
Iron deficiency anaemia, unspecified
D50.9 [45605373]
8.3e-01
2.3e+00
—
—
—
1.6e+00
1.9e+00
cases:1.59%
controls:0.70%
cases:2.85%
controls:0.28%
—
—
—
—
—
—
cases:1.74%
controls:0.35%
cases:6.41%
controls:0.98%
5
22
310
3128
9
9
307
3151
—
—
—
5
11
283
3093
15
27
219
2727
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
—
2.2e+00
—
—
1.0e+50
—
2.1e+00
—
—
cases:1.90%
controls:0.22%
—
—
—
—
cases:1.63%
controls:0.00%
—
—
cases:2.56%
controls:0.33%
—
6
7
310
3153
—
—
5
0
302
3154
—
6
9
228
2745
ferrous glycine sulfate; oral
B03AA01 [21601080]
1.5e+00
1.7e+00
—
—
—
2.8e+00
1.4e+00
cases:1.90%
controls:0.44%
cases:1.58%
controls:0.28%
—
—
—
—
—
—
cases:3.13%
controls:0.19%
cases:4.70%
controls:1.16%
6
14
309
3136
5
9
311
3151
—
—
—
9
6
279
3098
11
32
223
2722
Bacteria identified in Urine by Culture
630-4 [3026008]
3.8e-02
9.4e-01
1.9e+00
—
1.6e+00
1.3e+00
4.8e-01
cases:4.44%
controls:4.29%
cases:6.33%
controls:2.56%
cases:2.53%
controls:0.38%
—
—
cases:2.28%
controls:0.48%
cases:7.29%
controls:2.03%
cases:13.25%
controls:8.64%
14
135
301
3015
20
81
296
3079
8
12
308
3148
—
7
15
300
3139
21
63
267
3041
31
238
203
2516
carvedilol; oral
C07AG02 [21601700]
1.9e+00
2.0e+00
—
—
—
—
2.3e+00
cases:2.22%
controls:0.35%
cases:1.58%
controls:0.22%
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.22%
7
11
308
3139
5
7
311
3153
—
—
—
—
5
6
229
2748
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.4e-01
6.9e-01
1.1e+00
—
6.2e-01
1.0e+00
7.4e-01
cases:44.13%
controls:29.49%
cases:28.16%
controls:16.39%
cases:8.23%
controls:2.94%
—
—
cases:5.86%
controls:3.23%
cases:35.76%
controls:17.01%
cases:58.12%
controls:39.80%
139
929
176
2221
89
518
227
2642
26
93
290
3067
—
18
102
289
3052
103
528
185
2576
136
1096
98
1658
Otolaryngology
4 [38004449]
1.2e-01
8.5e-01
1.8e+00
—
1.3e+00
7.8e-01
7.6e-01
cases:11.43%
controls:10.29%
cases:8.23%
controls:3.70%
cases:2.85%
controls:0.51%
—
—
cases:2.28%
controls:0.63%
cases:8.33%
controls:3.99%
cases:20.51%
controls:10.78%
36
324
279
2826
26
117
290
3043
9
16
307
3144
—
7
20
300
3134
24
124
264
2980
48
297
186
2457
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
1.9e+00
—
—
—
1.0e+50
—
2.2e+00
cases:2.86%
controls:0.44%
—
—
—
—
—
—
cases:1.63%
controls:0.00%
—
—
cases:4.27%
controls:0.47%
9
14
306
3136
—
—
—
5
0
302
3154
—
10
13
224
2741
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
1.4e+00
1.6e+00
—
—
—
—
1.0e+00
cases:5.08%
controls:1.30%
cases:2.85%
controls:0.57%
—
—
—
—
—
—
—
—
cases:5.98%
controls:2.18%
16
41
299
3109
9
18
307
3142
—
—
—
—
14
60
220
2694

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
121
158
11.46
93.68
9.7
2.8
310.67
231.27
ng/l
0.73
116
141
90
93
12.89
81.62
5.7
2.3
20.89
22.13
s
0.53
84
83
59
29
24.51
79.40
1.5
1.2
2.31
1.60
u/ml
—
29
10
232
753
7.86
74.89
13.8
3.0
1453.24
1141.30
ng/l
1.07
225
630
53
28
22.32
68.93
1.3
1.2
—
—
—
0
0
190
547
6.76
68.32
9.5
2.4
385.96
322.93
umol/l
9.23
184
477
126
256
7.31
64.60
19.0
7.3
4.83
5.19
kpa
2.68
121
244
125
252
7.34
64.58
18.9
7.4
7.43
7.42
ph
0.53
82
146
126
257
7.28
64.33
18.9
7.3
9.88
11.84
kpa
6.34
121
246
123
251
7.18
62.61
19.2
7.4
1.16
0.88
mmol/l
0.26
100
211
87
141
8.00
54.46
5.1
4.7
—
—
—
0
0
203
803
4.91
45.66
11.8
3.0
27.67
33.86
u/l
1.64
198
764
45
38
13.54
45.49
7.9
3.9
6.36
8.68
kpa
5.15
45
38
37
23
17.97
44.16
2.5
2.1
—
—
—
0
0
245
1191
5.00
40.31
52.5
10.7
1.68
1.21
inr
20.77
225
974
180
720
4.26
38.15
6.1
2.3
3.31
3.03
mg/l
0.57
172
601
141
480
4.36
37.20
8.4
3.2
854.09
331.36
ng/l
0.36
129
363
118
358
4.56
36.16
1.7
1.4
670.27
583.33
titre
0.24
37
72
90
227
5.06
34.61
6.9
3.0
7.38
7.38
ph
0.10
65
143
147
547
4.02
33.68
8.2
1.7
1.56
1.57
mg/l
0.01
116
423
32
27
13.01
32.10
1.3
1.2
—
—
—
0
0
32
28
12.54
31.37
1.3
1.2
—
—
—
0
0
116
385
4.09
30.90
12.8
3.2
0.80
0.83
mmol/l
1.43
111
362
86
229
4.71
30.68
7.0
3.0
1.51
2.15
mmol/l
0.68
73
188
163
694
3.64
29.80
7.1
3.8
—
—
—
0
0
67
150
5.34
29.31
29.3
9.0
24.51
24.99
mmol/l
0.42
67
150
38
48
8.81
28.72
1.1
1.1
—
—
—
0
0
45
72
7.07
27.75
1.2
1.2
—
378.00
—
0
5
36
45
8.85
27.40
8.8
4.6
61.77
59.36
%
0.22
36
45
55
111
5.74
26.89
2.6
1.6
4.07
12.67
iu/ml
0.88
11
21
196
986
3.40
26.58
8.0
3.3
117.90
90.91
ng/l
0.09
171
688
76
207
4.46
26.06
31.1
6.2
—
—
—
0
0
186
919
3.32
25.76
14.4
6.2
—
—
—
0
0
29
30
10.49
25.35
4.4
1.6
—
—
—
0
0
29
30
10.49
25.35
4.4
1.6
—
—
—
0
0
29
30
10.49
25.35
4.4
1.6
—
—
—
0
0
29
30
10.49
25.35
4.4
1.6
—
—
—
0
0
218
1204
3.35
24.63
11.4
4.0
34.83
35.33
g/l
0.67
210
1118
31
38
8.89
23.89
8.8
4.0
2.21
1.83
mmol/l
0.30
24
24
31
38
8.89
23.89
8.8
4.0
5.05
4.88
kpa
0.61
31
38
224
1273
3.32
23.79
14.8
6.3
2.44
2.84
%
2.44
214
1170
225
1288
3.30
23.48
15.0
6.4
24.72
28.61
%
6.17
215
1207
223
1271
3.28
23.42
14.8
6.4
0.71
0.70
%
0.07
212
1161
93
315
3.71
23.36
27.4
6.6
104.48
104.15
mmol/l
0.22
93
315
223
1273
3.28
23.32
15.0
6.4
9.25
8.88
%
1.03
213
1172
33
48
7.52
22.05
1.1
1.0
—
—
—
0
0
95
341
3.50
21.68
3.8
1.7
—
—
—
0
0
67
191
4.14
21.39
2.0
2.8
—
—
—
0
0
84
289
3.55
20.36
3.3
2.7
2.22
1.67
%
3.02
79
260
226
1373
3.01
19.80
14.7
6.2
0.61
0.57
e9/l
1.81
208
1177
215
1276
2.93
19.60
14.9
6.3
59.88
56.51
%
3.82
210
1197
226
1380
2.98
19.48
14.7
6.2
0.04
0.04
e9/l
0.52
208
1183
231
1433
3.00
19.23
15.4
6.4
0.17
0.19
e9/l
1.13
215
1244
228
1410
2.96
18.98
15.3
6.2
1.62
1.98
e9/l
3.56
212
1242
46
108
4.78
18.73
2.2
2.0
1.11
1.48
g/l
1.72
37
95
114
507
2.90
17.62
4.5
2.5
500.31
533.52
mosm/kgh2o
1.07
103
448
77
277
3.32
17.18
1.6
1.4
—
—
—
0
0
236
1536
2.84
16.94
18.2
9.9
4.34
3.95
e9/l
1.61
219
1347
35
73
5.24
16.30
8.7
2.8
7.42
7.41
ph
0.92
35
73
148
778
2.62
16.25
4.9
2.1
176.35
261.39
u/l
0.39
143
745
205
1262
2.62
16.14
7.1
2.7
109.26
115.99
ug/l
0.17
199
1163
64
219
3.38
15.37
2.8
2.7
86.36
62.44
e9/l
3.06
47
164
19
6
33.44
14.97
1.3
1.3
30.84
27.50
s
—
19
6
51
153
3.76
14.94
39.1
8.5
92.20
94.46
%
0.84
51
153
36
83
4.74
14.91
1.1
1.2
—
—
—
0
0
49
144
3.82
14.78
40.4
8.6
0.64
0.66
%
0.20
49
144
50
150
3.75
14.63
39.7
8.4
1.25
1.27
%
0.06
50
150
119
587
2.60
14.61
4.4
2.3
3.63
7.31
e6/l
1.82
108
534
213
1376
2.52
14.52
20.9
5.9
1.18
1.22
mmol/l
10.22
194
1178
198
1247
2.45
14.13
20.3
5.4
1.18
1.22
mmol/l
11.17
190
1125
29
58
5.38
14.11
3.9
3.1
0.80
0.80
nmol/l
0.03
24
46
146
806
2.44
13.95
7.4
3.5
7.41
7.40
ph
3.26
122
578
51
160
3.58
13.95
1.2
1.3
323.44
148.31
u/ml
—
10
64
22
36
6.47
13.10
5.5
2.6
—
—
—
0
0
222
1528
2.36
12.16
17.7
4.1
6.70
6.34
mmol/l
2.12
216
1442
17
9
19.82
11.71
2.7
9.0
17.62
13.17
%
—
17
9
93
449
2.49
11.58
1.7
1.9
—
—
—
0
0
82
373
2.59
11.57
1.6
1.7
—
—
—
0
0
62
246
2.87
11.40
9.1
4.3
0.76
0.72
%
0.06
27
72
134
764
2.26
11.37
5.9
2.8
0.54
0.44
e6/l
0.19
117
560
69
293
2.71
11.15
4.1
2.8
10.40
8.07
umol/l
0.70
63
258
60
237
2.87
11.11
9.6
4.7
0.52
0.29
%
0.17
23
52
147
880
2.20
10.98
5.9
2.8
50.74
147.33
e6/l
0.60
129
659
59
234
2.85
10.83
8.8
4.2
0.65
0.46
%
0.48
26
65
184
1208
2.17
10.81
25.4
10.3
0.00
0.00
e9/l
0.20
160
998
21
41
5.40
10.45
3.8
3.7
4.32
3.99
e9/l
0.34
21
41
47
170
3.05
10.15
8.4
4.0
7.42
7.42
ph
0.42
41
140
17
14
12.72
9.96
4.7
3.2
34.75
115.23
ug/l
1.25
17
14
57
235
2.72
9.68
9.0
4.4
0.05
0.08
%
0.26
22
60
42
148
3.10
9.47
4.4
3.1
4.08
4.54
pmol/l
1.97
36
134
13
6
22.46
9.42
2.1
2.0
—
—
—
0
0
136
831
2.08
9.26
11.7
6.2
—
—
—
0
0
64
296
2.44
8.55
3.3
1.6
—
—
—
0
0
53
224
2.62
8.54
2.6
2.3
61.33
31.52
u/l
0.48
46
186
22
54
4.29
8.40
1.3
1.3
132.36
163.56
au/ml
0.68
11
16
37
130
3.08
8.37
8.5
4.1
—
—
—
0
0
20
31
6.79
8.32
4.1
3.6
—
—
—
0
0
110
646
2.05
8.15
3.6
2.8
53.28
28.83
mg/l
0.56
85
367
35
123
3.06
7.91
6.2
2.8
0.59
0.62
%
0.19
35
123
35
124
3.04
7.80
6.2
2.8
1.30
1.11
%
0.67
35
124
89
490
2.11
7.80
1.3
1.3
38.82
38.01
iu/ml
0.03
24
139
27
82
3.49
7.70
2.0
1.3
27.63
1.46
u/ml
—
6
8
140
909
1.93
7.70
3.5
3.0
—
—
—
0
0
109
653
1.99
7.56
4.1
3.3
9.60
5.25
mg/mmol
0.43
85
351
102
598
2.02
7.51
10.3
4.9
—
—
—
0
0
17
25
7.11
7.39
1.3
1.5
—
—
—
0
0
151
1017
1.89
7.34
7.6
3.4
64.75
142.94
e6/l
0.55
128
700
11
7
16.18
7.27
4.4
1.0
—
—
—
0
0
81
444
2.09
7.12
5.0
2.6
3.21
2.44
e6/l
0.32
51
217
129
833
1.90
7.08
4.0
2.4
—
—
—
0
0
54
252
2.36
7.02
3.2
1.5
—
—
—
0
0
47
206
2.49
7.00
3.3
2.2
106.26
64.10
ng/l
2.85
42
177
112
704
1.89
6.59
3.7
2.8
6.18
7.23
mmol/l
2.37
106
576
15
23
6.77
6.41
2.2
2.0
86.66
89.13
%
0.50
15
23
60
313
2.12
5.94
4.5
1.4
—
—
—
0
0
39
174
2.41
5.58
1.7
1.4
—
—
—
0
0
21
68
3.23
5.44
3.4
2.6
4.00
2.21
index
0.50
13
38
87
534
1.85
5.38
1.8
1.6
415.80
41163241.91
pmol/l
0.75
73
430
21
69
3.18
5.32
4.1
2.8
59.81
57.70
%
0.41
21
69
8
6
13.62
5.10
1.4
1.2
—
—
—
0
0
94
600
1.79
5.09
2.3
1.4
2.09
2.24
g/l
0.42
71
342
15
32
4.86
5.05
1.1
1.1
—
—
—
0
0
227
1854
1.70
4.83
7.7
4.1
—
3.08
—
0
7
13
25
5.37
4.82
2.1
2.0
52.50
37.71
ug/min
—
6
12
79
486
1.82
4.80
1.9
1.7
1073.58
1227.11
nmol/l
0.84
67
343
22
80
2.87
4.71
5.5
5.6
1.70
1.17
mmol/l
0.88
22
80
12
23
5.37
4.50
2.1
1.7
10.62
10.26
mmol/l
0.16
12
23
18
60
3.11
4.47
1.1
2.2
—
—
—
0
0
41
206
2.13
4.45
4.9
3.6
1.22
1.23
mmol/l
0.40
36
175
23
89
2.70
4.41
1.3
1.5
—
—
—
0
0
158
1196
1.61
4.38
4.7
2.8
—
—
estimate
—
0
0
10
16
6.41
4.32
2.2
1.3
1.00
1.06
index
—
10
16
13
30
4.47
4.17
2.6
2.2
30.77
32.33
pg
0.61
13
30
10
17
6.03
4.16
2.6
9.9
11.94
11.04
%
—
10
17
11
24
4.70
3.77
1.1
1.3
—
—
—
0
0
6
5
12.18
3.77
5.5
2.4
47.92
60.80
%
—
6
5
7
9
7.91
3.57
1.1
8.8
10.19
6.81
mmol/l
—
7
9
13
36
3.71
3.53
1.8
1.3
—
—
—
0
0
20
81
2.56
3.53
3.6
4.3
68.81
47.69
mg/l
0.17
14
71
9
17
5.41
3.53
1.1
1.1
—
—
—
0
0
19
75
2.63
3.53
3.7
4.0
1.50
2.71
ratio
0.78
11
42
12
31
3.98
3.52
2.0
1.4
—
—
—
0
0
20
82
2.53
3.45
3.6
4.3
37.67
106.16
mg/l
0.48
15
72
7
10
7.12
3.38
1.3
1.5
—
—
—
0
0
5
188
0.25
3.37
2.0
2.3
8.21
13.11
nmol/l
—
5
169
233
2605
0.65
3.13
5.6
5.2
2.37
2.78
mmol/l
11.79
225
2360
37
206
1.90
3.06
8.3
3.4
—
—
—
0
0
14
51
2.82
3.02
4.4
2.4
1.55
1.49
mmol/l
0.11
14
51
225
2528
0.66
3.01
5.0
4.6
1.38
1.55
mmol/l
6.70
214
2281
48
294
1.74
2.92
1.6
1.4
—
—
—
0
0
7
13
5.47
2.88
2.4
3.5
908.57
823.23
u/ml
—
7
13
66
937
0.63
2.83
2.5
2.8
—
—
—
0
0
12
39
3.15
2.80
6.2
3.8
—
—
—
0
0
153
1232
1.45
2.79
3.9
2.4
75.45
78.55
nmol/l
0.68
143
1077
5
6
8.43
2.76
6.4
1.3
—
—
—
0
0
12
40
3.07
2.72
2.3
1.3
30.64
5.31
pmol/l
0.61
12
40
228
2540
0.68
2.71
5.2
4.6
4.21
4.75
mmol/l
14.09
220
2312
19
86
2.28
2.69
1.3
1.2
—
—
—
0
0
52
339
1.63
2.53
1.3
1.2
—
—
—
0
0
201
1723
1.42
2.49
5.4
3.0
65.06
43.26
u/l
4.17
194
1587
16
70
2.35
2.45
7.1
4.7
3.94
3.90
mmol/l
0.16
16
70
6
13
4.68
2.28
5.7
3.5
327.33
55.62
nmol/l
—
6
13
15
66
2.33
2.28
3.7
1.8
126.33
124.79
g/l
—
9
48
25
136
1.91
2.25
1.3
1.3
—
—
—
0
0
8
25
3.25
2.11
1.8
1.6
20.15
36.54
ng/l
—
8
25
96
745
1.41
2.03
5.6
3.2
0.00
0.13
estimate
0.63
50
231
8
26
3.13
2.02
1.4
1.1
—
—
—
0
0
107
847
1.39
2.02
1.9
1.6
18.64
20.86
nmol/l
0.76
101
677
6
16
3.80
1.94
1.3
2.5
47.32
36.84
%
—
6
16
13
58
2.29
1.93
2.1
2.0
—
—
—
0
0
233
2541
0.72
1.91
5.2
4.7
6.02
5.73
mmol/l
2.72
220
2271
125
1024
1.35
1.89
6.0
3.2
2.32
2.36
mmol/l
3.13
120
903
7
23
3.09
1.81
5.7
3.1
34.57
2.81
nmol/l
—
7
23
167
1439
1.32
1.76
7.1
3.7
0.00
1.07
estimate
0.50
61
281
84
1055
0.73
1.74
2.0
1.8
1.36
1.25
mmol/l
0.67
73
877
17
89
1.96
1.73
2.2
2.4
290.25
157.91
mg/l
—
8
32
7
25
2.84
1.66
4.0
1.6
4.11
4.00
mmol/l
—
7
25
5
14
3.61
1.62
1.4
1.3
2.16
1.76
mmol/l
—
5
14
163
1412
1.30
1.60
6.8
3.6
0.00
0.00
estimate
0.50
62
277
131
1112
1.29
1.47
4.9
3.3
6.23
6.30
ph
0.32
73
593
9
38
2.41
1.46
2.1
1.8
—
—
—
0
0
5
16
3.16
1.44
1.0
1.0
—
—
—
0
0
21
127
1.70
1.40
2.2
2.4
—
—
—
0
0
7
29
2.44
1.40
1.6
1.1
—
—
—
0
0
9
41
2.23
1.38
5.7
2.4
10.22
6.71
mmol/l
—
9
41
222
2400
0.78
1.36
4.5
3.9
1.27
1.19
mmol/l
1.51
213
2139
5
17
2.97
1.36
1.6
1.3
—
—
—
0
0
5
17
2.97
1.36
1.6
1.9
1244.20
279.35
mg
—
5
17
6
24
2.53
1.31
1.0
1.6
—
—
—
0
0
97
805
1.29
1.28
7.1
3.6
0.00
0.00
estimate
0.50
56
266
83
675
1.31
1.27
1.4
1.3
0.60
1.45
u/ml
1.88
27
165
162
1433
1.25
1.25
7.0
3.7
0.00
5.72
estimate
0.50
63
284
6
25
2.42
1.25
4.5
1.6
104.17
107.00
mmol/l
—
6
25
6
25
2.42
1.25
4.5
1.6
1.17
1.19
mmol/l
—
6
25
30
208
1.49
1.18
2.8
2.0
0.25
0.90
e6/l
1.72
30
197
5
20
2.52
1.15
1.0
1.0
—
—
—
0
0
7
30
2.36
1.13
1.0
1.1
—
—
—
0
0
5
21
2.40
1.09
1.4
2.3
—
—
—
0
0
7
32
2.21
1.08
1.1
1.2
98.43
123.12
pmol/l
—
7
32
11
59
1.89
1.08
1.1
1.2
—
—
—
0
0
85
716
1.25
0.98
1.5
1.4
—
—
—
0
0
8
144
0.54
0.95
2.0
2.0
—
—
—
0
0
6
120
0.49
0.95
1.3
1.8
—
—
—
0
0
137
1218
1.21
0.95
2.3
2.0
82.62
99.65
pmol/l
4.72
83
625
57
459
1.29
0.95
1.3
1.3
38.90
10.30
u/ml
0.67
15
164
29
211
1.41
0.92
5.0
2.9
6.13
6.07
ph
0.14
24
138
0
25
0.00
0.79
0.0
1.3
—
—
—
0
0
119
1066
1.18
0.73
6.6
3.7
0.02
0.07
estimate
0.79
52
243
31
239
1.33
0.72
1.2
1.2
—
—
—
0
0
16
109
1.49
0.72
1.3
1.2
—
—
—
0
0
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
7
43
1.64
0.67
1.3
1.2
—
—
—
0
0
18
244
0.72
0.63
1.3
1.6
—
—
—
0
0
10
63
1.61
0.62
3.0
3.5
—
—
—
0
0
0
21
0.00
0.60
0.0
2.5
—
—
—
0
0
0
22
0.00
0.59
0.0
11.2
—
674.45
—
0
22
17
123
1.40
0.59
3.9
1.7
0.00
0.00
estimate
-0.00
11
35
0
23
0.00
0.58
0.0
15.8
—
1209.00
—
0
23
12
81
1.50
0.58
1.2
2.1
0.96
8587.27
u/l
—
5
26
34
406
0.82
0.48
2.5
3.0
0.66
0.82
ug/l
0.74
21
255
31
257
1.23
0.45
3.3
1.9
0.00
0.00
estimate
—
9
46
13
173
0.74
0.43
1.4
1.4
—
26.55
—
0
19
0
17
0.00
0.41
0.0
1.3
—
186.44
—
0
17
7
101
0.69
0.40
1.0
1.0
—
—
—
0
0
9
69
1.31
0.37
1.7
1.1
3.11
3.53
mmol/l
—
9
63
36
310
1.18
0.37
2.4
4.5
36.04
35.91
ug/l
0.00
25
256
5
37
1.36
0.37
1.0
1.2
—
—
—
0
0
270
2642
1.12
0.30
48.6
13.8
22.77
25.17
mg/l
0.65
259
2108
15
185
0.80
0.30
1.5
1.2
—
—
—
0
0
7
54
1.30
0.30
1.6
1.2
—
—
—
0
0
42
374
1.14
0.30
1.8
2.5
303.69
122.85
ug/g
0.50
36
274
10
76
1.33
0.28
2.2
2.8
—
—
—
0
0
8
65
1.24
0.27
1.9
1.1
45.63
3.40
e6/l
—
8
45
8
66
1.22
0.27
1.9
1.2
110.63
169.34
e6/l
—
8
47
65
601
1.10
0.26
4.2
2.8
2.47
2.46
mmol/l
0.17
57
532
26
227
1.16
0.24
1.8
1.4
—
—
—
0
0
9
77
1.17
0.24
2.0
1.2
504.89
427.72
mg/l
—
9
71
270
2745
0.91
0.23
39.1
12.0
—
—
—
0
0
8
102
0.78
0.21
1.0
1.1
—
—
—
0
0
214
2089
1.07
0.21
6.0
4.2
15.71
14.82
pmol/l
5.45
203
1884
67
628
1.08
0.20
6.1
4.1
1.02
1.02
kg/l
0.71
50
410
62
660
0.93
0.19
4.3
5.7
2.98
3.54
ug/l
0.21
52
580
10
82
1.23
0.17
2.4
1.6
—
—
—
0
0
5
70
0.71
0.17
1.0
4.6
18.60
31.43
u/ml
—
5
70
18
158
1.15
0.16
2.9
2.7
96.63
129.88
u/ml
0.26
18
153
10
83
1.21
0.15
2.4
1.6
—
—
—
0
0
10
83
1.21
0.15
2.4
1.6
—
—
—
0
0
7
87
0.80
0.14
1.7
1.3
—
—
—
0
0
10
84
1.20
0.14
15.7
9.9
—
—
—
0
0
10
85
1.18
0.12
2.4
1.6
—
—
—
0
0
26
240
1.09
0.11
1.3
1.9
—
—
—
0
0
16
144
1.12
0.10
1.2
1.2
—
142.00
titre
—
0
5
5
44
1.14
0.10
2.4
1.4
—
—
—
0
0
248
2466
1.02
0.04
8.8
5.2
2.12
1.95
mu/l
1.53
238
2228
35
343
1.02
0.01
1.3
1.3
—
—
—
0
0
107
1068
1.00
0.00
2.7
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
0.00
—
0
6
7
78
0.90
-0.00
3.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
57.67
—
0
6
0
5
0.00
-0.00
0.0
2.2
—
14.46
—
0
5
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
7.53
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
67.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
4.75
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
5.6
—
3.47
—
0
9
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
0.48
—
0
7
0
8
0.00
-0.00
0.0
6.1
—
3.46
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
3.42
—
0
5
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.02
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint I9_HYPTENSPUL and mortality.

Females

Parameter HR [95% CI] p-value
I9_HYPTENSPUL 4.18 [3.33, 5.24] < 0.001
Birth year 0.994 [0.99, 1.0] 0.19

During the follow-up period (1.1.1998 — 31.12.2019), 588 out of 1066 females with I9_HYPTENSPUL died.

Males

Parameter HR [95% CI] p-value
I9_HYPTENSPUL 4.585 [3.19, 6.59] < 0.001
Birth year 0.99 [0.98, 1.0] 0.026

During the follow-up period (1.1.1998 — 31.12.2019), 390 out of 643 males with I9_HYPTENSPUL died.

Mortality risk

Mortality risk for people of age

years, who have I9_HYPTENSPUL.

N-year risk Females Males
1 0.421% 0.888%
5 2.404% 5.63%
10 6.259% 13.925%
15 11.562% 25.475%
20 19.153% 39.831%

Relationships between endpoints

↥

Index endpoint: I9_HYPTENSPUL – Hypertension, Pulmonary Arterial

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data